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ABSTRACT OF DISSERTATION 
 
 
Regulation of 7-Dehydrocholesterol Reductase by Vitamin D3 
7-Dehydrocholesterol (7-DHC) is the substrate of 7-dehydrocholesterol reductase 
(DHCR7) in the cholesterol synthesis pathway. Keratinocytes in human skin 
possess the enzymes necessary for cholesterol synthesis but are also 
responsible for vitamin D3 synthesis from 7-DHC by exposure to UVB irradiation. 
It has been well established that DHCR7 is regulated by the SREBP pathway in 
the regulation of cholesterol synthesis, but little is known about the regulation of 
DHCR7 by the vitamin D pathway. In this study, the regulation of DHCR7 activity 
by vitamin D was explored. Treatment of adult human epidermal keratinocyte 
(HEKa) cells with vitamin D3 resulted in a rapid decrease in DHCR7 activity which 
was not due to changes in the amount of enzyme present. This suppression of 
activity was observed only in HEKa cells, a primary cell line cultured from normal 
human skin, and not in an immortalized skin cell line (HaCaT cells) nor in two 
liver-derived hepatoma cell lines. Because vitamin D3 treatment of HEKa cells did 
not change the content of lanosterol nor 7-DHC, these results suggest that 
vitamin D3 rapidly down-regulates the entire cholesterolgenesis pathway, 
presumably at a very early step in the pathway. 25-Hydroxyvitamin D3, the first 
metabolite and circulating form of vitamin D3, had a lesser effect on DHCR7 
activity, while 1,25-dihydroxyvitamin D3, the activated form of the vitamin, had no 
effect on DHCR7, indicating that the vitamin D receptor is not involved. The 
decrease in DHCR7 activity was due neither to the dephosphorylation of the 
enzyme, an established mechanism of inactivation, nor to direct inhibition by 
vitamin D3. Vitamin D3 markedly inhibited proliferation and induced differentiation 
of HEKa cells, suggesting a possible role for hedgehog signaling in the decrease 
in DHCR7 activity.  
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Chapter 1: Introduction 
1.1 Cholesterol function and homeostasis 
1.1.1 Cholesterol function 
Cholesterol is an essential lipid in many eukaryotic organisms (Burger, Gimpl et 
al. 2000). Mammalian cells require cholesterol for membrane biogenesis, cell 
growth, and synthesis of steroid hormones and bile acids (Liscum and Munn 
1999). 
Cholesterol is a key component of biological membranes. It is nonrandomly 
distributed between cellular organelles, subdomains of membranes, and leaflets 
of the membrane bilayer. In eukaryotic cells, about 65%-90% of cellular free 
cholesterol may reside in the plasma membrane where its average concentration 
is about 200-300 μg/mg protein. Cholesterol influences many of the biophysical 
properties of membranes such as fluidity and permeability. It can modulate 
membrane receptor function by either binding directly to the protein thereby 
altering, for example, the conformation of the protein, or influencing the receptor 
indirectly by changing the biophysical properties of the membrane lipid bilayer 
(Burger, Gimpl et al. 2000). 
As cholesterol is present in the lipoprotein membranes of the nucleus, 
mitochondria, and microsomes, as well as the plasma membrane, it is not 
surprising that a supply of cholesterol would be required for the membrane 
proliferation that must accompany cell growth(Siperstein 1984). This was first 
supported by the observation that 25-hydroxy- or 20-hydroxycholesterol, which 
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inhibits HMG-CoA reductase, the rate limiting enzyme in cholesterol synthesis, 
blocked the growth and proliferation of mouse L cells (Chen, Kandutsch et al. 
1974). Further exploration suggested that cholesterol is required for cell growth 
during the early G1 phase of the cell cycle (Quesney-Huneeus, Galick et al. 1983) 
and loss of cholesterol feedback control is observed in premalignant and 
malignant cells (Siperstein 1984). 
Cholesterol is the precursor molecule in the synthetic pathways of steroid 
hormones and bile acids. The rate-limiting step of steroid hormone biosynthesis 
occurs in mitochondria where free cholesterol (from the hydrolysis of cholesterol 
esters) is converted to pregnenolone by cholesterol side-chain cleavage enzyme 
(P450scc). Further metabolism of pregnenolone leads to the steroidogenesis of 
progestogens, mineralocorticoids, glucocorticoids, androgens, and estrogens 
(Hanukoglu 1992). In the liver, cholesterol is converted to bile acids via 
cytochrome P450-mediated oxidation. In the human and rat, the primary bile 
acids are cholic acid and chenodeoxycholic acid (Andersson, Davis et al. 1989) 
which are secreted into the lumen of the intestine to form deoxycholic acid and 
lithocholic acid, respectively, functioning as emulsifiers to facilitate the absorption 
of dietary fat and fat-soluble vitamins. 
1.1.2 Cholesterol homeostasis 
Hypercholesterolaemia is one of the major causes of atherosclerosis (Bhatnagar, 
Soran et al. 2008). To maintain cholesterol homeostasis in mammals, three 
separate metabolic pathways have developed and are coordinately regulated. 
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Two pathways function in the supply of cholesterol to cells. The first one is the 
endogenous biosynthetic pathway in which cholesterol is synthesized from 
acetate precursors. The second one is the exogenous pathway in which dietary 
cholesterol is absorbed by the intestine. The liver responds to the dietary 
cholesterol by decreasing hepatic cholesterol synthesis (Lu, Lee et al. 2001). A 
third pathway functions in the catabolism of cholesterol and involves the 
conversion of the molecule into bile acids (Andersson, Davis et al. 1989).  
1.1.2.1 Cholesterol biosynthesis, uptake, storage and metabolism 
The endoplasmic reticulum (ER) is the site of cholesterol biosynthesis (Maxfield 
and Wustner 2002). Synthesis (Fig 1.1) starts with one molecule of acetyl CoA 
and one molecule of acetoacetyl CoA, which are hydrated by 3-hydroxy-3-
methyglutaryl CoA (HMG-CoA) synthase to form HMG-CoA. This molecule is 
then reduced to mevalonate by HMG-CoA reductase, the rate-limiting enzyme in 
the cholesterologenic pathway (Goldstein and Brown 1990). Mevalonate is then 
converted into isopentenyl pyrophosphate. Squalene, which is composed of six 
isopentenyl pyrophosphate units, is cyclized into lanosterol by the action of 
squalene monooxygenase. Finally, lanosterol is converted into cholesterol 
through a 19-step process (Vance and Van den Bosch 2000). Notably, 7-
dehydrocholesterol reductase catalyzes the last step in cholesterol synthesis in 
mammals and ergosterol synthesis in fission yeast (Espenshade and Hughes 
2007). 
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Dietary sources of cholesterol from egg yolks and cheese, etc. are available for 
use by cells through the low-density lipoprotein (LDL) pathway (Goldstein and 
Brown 1977). Free cholesterol in the diet is solubilized into micelles formed from 
bile acids and then absorbed into enterocytes. Within enterocytes, cholesterol is 
esterified and packaged into chylomicrons which are subsequently secreted into 
the circulation.  The cholesterol-carrying lipoprotein particles in the blood are 
then delivered to the liver by LDL receptor-mediated internalization (Lee, Gordon 
et al. 2001). It consists of an ordered sequence of events in which LDL is first 
bound to a high-affinity receptor (LDL receptor) on the cell surface, and is then 
internalized by endocytosis and delivered to lysosomes where the cholesteryl 
esters are hydrolyzed to free cholesterol for cell use. 
Adipose tissue is the major site of cholesterol storage. Most of the cholesterol in 
fat tissue is localized in the central oil droplet of the fat-storing adipocyte (Angel 
and Farkas 1974). 
Four enzymes are critical to bile acid biosynthesis: CYP7A1, CYP7B1, CYP27 
and CYP8B. The conversion of cholesterol to the primary bile acids, cholic acid 
and chenodeoxycholic acid (CDCA) occurs via either the classic or mitochondrial 
pathway. In the classic pathway, the first and rate-limiting step is the addition of a 
hydroxyl group on position 7 of the steroid nucleus by the enzyme cholesterol 7α-
hydroxylase (CYP7A1 gene product). This reaction is followed by over a dozen 
reactions to form the primary bile acids. In the mitochondrial pathway, the side-
chain of cholesterol is firstly hydroxylated by the mitochondrial CYP27 gene 
product to generate substrate for the oxysterol 7α-hydroxylase (CYP7B1 gene 
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product). This pathway preferentially produces CDCA, whereas the classic 
pathway produces both cholic acid and CDCA (Repa and Mangelsdorf 2000). 
1.1.2.2 Regulation of cholesterol homeostasis 
Cholesterol homeostasis is predominantly achieved through repression of 
transcription of genes that govern the synthesis of cholesterol and its receptor-
mediated uptake from plasma lipoproteins (Goldstein and Brown 1990). 
Mammalian cells lack the capacity to directly degrade the four-membered ring 
structure of cholesterol; thus, the bile acid pathway represents the major 
mechanism for disposal of cholesterol from the body (Andersson, Davis et al. 
1989). 
The regulation of the cholesterol biosynthetic pathway is of particular importance 
because cholesterol must be supplied for many cellular functions. Failure in 
control of the pathway leads to solid crystal formation within cells or deposition of 
cholesterol in arteries, initiating atherosclerosis (Brown and Goldstein 1997). A 
finely tuned end-product feedback suppression mechanism is developed to 
govern cholesterol biosynthesis. This is established by the finding that diets rich 
in cholesterol decreased cholesterol de novo synthesis. Several enzymes are 
involved in this regulation including HMG-CoA synthase, HMG-CoA reductase, 
farnesyl diphosphate synthase, and squalene synthase (Brown and Goldstein 
1997). HMG-CoA reductase is the most extensively studied since it controls the 
rate-limiting step in cholesterol biosynthesis. HMG-CoA reductase is among the 
most highly regulated enzyme in nature (Goldstein and Brown 1990). Addition of 
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HMG-CoA reductase inhibitor, such as compactin and lovastatin, to cultured cells 
yields a 200-fold induction in HMG-CoA reductase protein within a few hours 
(Nakanishi, Goldstein et al. 1988). This is the result of the multiplicative effect of 
smaller changes occurring at three levels: induction of transcription produces an 
eightfold increase in mRNA levels, each mRNA is translated at a fivefold higher 
rate, and the enzyme molecules are degraded fivefold more slowly (Goldstein 
and Brown 1990). Further studies revealed that a family of membrane-bound 
transcription factors called sterol regulatory element binding protein (SREBP) 
and the sterol regulatory element-1 (SRE-1) in the promoter of the HMG-CoA 
reductase gene are responsible for the cholesterol-mediated inhibition of 
transcription (Osborne, Goldstein et al. 1985). In addition, the NH2-terminal 
membrane-attachment domain of HMG-CoA reductase has a sterol-sensing 
function in which the regulated degradation of this enzyme is dependent on when 
sterols accumulate (Brown and Goldstein 1997). Another level of regulation on 
HMG-CoA reductase is the rapid inhibition of the enzyme by phosphorylation of 
serine871 through the action of AMP-activated protein kinase (AMPK) (Omkumar, 
Darnay et al. 1994). Statins inhibit HMG-CoA reductase to lower serum 
cholesterol and thus reduce the risk for cardiovascular disease. Green and black 
tea extracts also inhibit HMG-CoA reductase by directly inhibiting the enzyme 
and activating AMPK and the concomitant phosphorylation of HMG-CoA 
reductase (Singh, Banerjee et al. 2009). 
The other major source of cholesterol is derived from LDL receptor-mediated 
endocytosis. Patients who suffered from familial hypercholesterolaemia have 
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genetic defects involving specific steps in the LDL pathway. As a result, the cells 
fail to bind and take up the lipoprotein with high affinity. Because these cells are 
unable to utilize LDL-cholesterol, they must satisfy their cholesterol requirement 
by synthesizing large amounts of cholesterol de novo (Goldstein and Brown 
1977). In vitro, in the absence of LDL, animal cells maintain high activities of the 
HMG-CoA synthase and HMG-CoA reductase, thereby synthesizing an 
excessive amount of cholesterol. When LDL is present, HMG-CoA synthase and 
reductase activities decline by more than 90%. When cellular sterols rise or when 
cell growth ceases and cholesterol demand declines, the LDL receptor gene is 
repressed (Goldstein and Brown 1990).  
To balance the pool of cholesterol, cells develop an intricate series of reactions 
to modify cholesterol to form bile acids: small, soluble, and detergent-like 
molecules so that excess cholesterol can be readily eliminated. The catabolism 
of cholesterol to bile acids is transcriptionally regulated by both feed-forward and 
feedback signaling pathways mediated by cholesterol-derived oxysterols and bile 
acids, respectively (Repa and Mangelsdorf 2000). LXRα is activated by 
oxysterols to increase Cyp7α transcription (Janowski, Willy et al. 1996). When 
fed high cholesterol diets, rats and mice respond in part by synthesizing more 
bile acids through the classic pathway, whereas LXRα-/- mice fail to induce 
Cyp7α transcription and accumulate enormous amount of cholesterol in the liver. 
The most active ligands for LXRα are the 24-hydroxycholesterol and 24,25-
epoxycholesterol (Russell 1999). Oxysterols also block the cleavage of SREBPs 
and the subsequent migration of the amino-terminal fragments to the nucleus to 
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activate the expression of many genes in the cholesterol supply and fatty acid 
synthesis pathways (Lund, Kerr et al. 1998). FXR, a bile acid receptor, is a global 
regulator of bile acid metabolism, modulating both synthetic output in the liver 
and recycling in the intestine. When the bile acid pool size in an animal is 
increased by dietary bile acids, transcription from Cyp7α is decreased and that 
from ileal bile acid binding protein (IBABP), a transporter on the apical surface of 
the hepatocyte, is increased (Russell 1999).  
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Figure 1.1 Overview of the cholesterol biosynthetic pathway [modified from 
(Herman 2003)]. 
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1.2 Structure and function of mammalian skin 
1.2.1 Function of  mammalian skin 
Skin is the frontier of the mammalian body which shields the host from a variety 
of insults including mechanical cuts and abrasions, UV-irradiation, chemicals, 
pathogenic microorganisms, etc. To survive these insults, the skin performs a 
variety of specialized functions such as thermoregulation, sensation, 
immunological protection, and water and electrolyte preservation (Ziboh and 
Chapkin 1988, Feingold 2007, Proksch, Brandner et al. 2008). 
Another function of the skin is that it is the site where vitamin D photosynthesis 
occurs. Indeed, the epidermis is the major source of vitamin D for the body (Bikle 
2011). 
1.2.2 Structure of mammalian skin 
The mammalian skin is composed of two primary layers, the epidermis and the 
dermis. Epidermis is the first line of defense and protection (Alonso and Fuchs 
2003). 
The epidermis is composed of multiple layers (Fig 1.2). From the inner to the 
outermost are the stratum basale, the stratum spinosum, the stratum granulosum 
(SG) and the stratum corneum (SC). Within the epidermis, the major cell type is 
the keratinocyte which undergoes a continuous process of self-renewal as they 
progressively differentiate towards the outermost layer of the tissue (Swanson 
2004).  
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Figure 1.2 A diagram of human skin layers (Swanson 2004). 
Keratinocytes of the basal layer are relatively undifferentiated (Alonso and Fuchs 
2003). The primary function of the basal cell layer is that of mitotic activity in 
which the epidermal stem cells and the transiently amplifying cells pass through 
a series of physiological and biochemical events to proliferate. As the population 
of basal cells expands, some cells detach from the basement membrane and 
begin to move outward toward the skin surface (Nicoll and Cortese 1972, Alonso 
and Fuchs 2003). High resolution radioautography analysis of the kinetics on 
human epidermal cell populations showed that epidermal cell renewal time was 
between 13 to 18 days. Interestingly, these cells migrate at different speeds and 
are not rigidly bound to each other (Nicoll and Cortese 1972). As epidermal cells 
move away from the basal cell layer they enter the synthetic stage of 
differentiation, during which they are no longer dividing but are concentrating on 
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the formation of three major cellular constituents: the filamentous bundles, the 
membrane coating granules, and the keratohyalin granules. The second major 
phase of differentiation, the transformation phase, is the conversion of the 
granular cell into a cornified cell (Nicoll and Cortese 1972). At the molecular level, 
markers are indicators of the progress of differentiation. As the basal epidermal 
cells commit to differentiation, keratins K5 and K14 are downregulated while K1 
and K10 are upregulated. Profilaggrin is produced when the spinous cells reach 
the granular layer and filaggrin is synthesized in the transition zone between the 
granular and cornified layer. Involucrin is a marker of differentiated keratinocytes 
of the cornified envelope (Swanson 2004). 
The stratum corneum consists of corneocytes surrounded by a neutral lipid-
enriched extracellular matrix. The mechanical strength of the skin is provided by 
the corneocytes, which are encased by a cornified envelope consisting of 
extensively cross-linked proteins. The hydrophobic extracellular lipid matrix 
provides the barrier to the movement of water and electrolytes (Feingold 2007).  
1.2.3 Regulation of epidermal lipogenesis 
Mammalian epidermis is an active site of de novo lipid biosynthesis (Monger, 
Williams et al. 1988). As keratinocytes differentiate, there is a shift in intercellular 
lipid composition from a mixture of polar lipids and neutral lipids to sphingolipids 
and neutral lipids which have an important effect on both barrier function and 
desquamation (Elias and Feingold 1988).  
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It is generally accepted that the barrier function of the skin is mainly dependent 
on the stratum corneum (Nicoll and Cortese 1972) and the lipids are important for 
the cutaneous primary function (Grubauer, Feingold et al. 1987). Unlike the lipids 
that constitute most biological membranes, the lipids in the extracellular matrix of 
the stratum corneum are unique. The lipid mixture consists of roughly equimolar 
concentrations of ceramides, free fatty acids, and cholesterol while little 
phospholipid is present (Feingold 2007). Ceramides are particularly critical for 
barrier function because they are long-chain and highly saturated (Elias and 
Feingold 1988). A more recent study proposed that the lipids are organized as 
stacked bilayers of fully extended ceramides with cholesterol molecules 
associated with the ceramide sphingoid moiety and free fatty acid at the 
ceramide fatty acid end (Iwai, Han et al. 2012).  
Both in vivo and in organ culture, the rate of epidermal lipogenesis is higher in 
the stratum granulosum of neonatal mouse epidermis than in the subjacent 
basal/spinous layers (Elias and Feingold 1988). The lipid biosynthetic activity in 
vitro also was two- to fivefold higher in the stratum granulosum than in 
basal/spinous layers while other forms of metabolic activity such as protein and 
DNA synthesis are diminishing. The surprising observation that the highest rates 
of de novo synthesis occurred in differentiating, outer epidermal cell layers rather 
than in the proliferating compartment suggests that the epidermal lipid 
biosynthesis may be largely directed towards provision of the cutaneous 
permeability barrier, rather than in supplying lipids for membrane synthesis in 
response to requirements for cellular growth and replication (Monger, Williams et 
 14 
 
al. 1988). This is further supported by the evidence that epidermal cholesterol 
synthesis is increased during permeability barrier repair (Proksch, Elias et al. 
1990) and topical application of statins which inhibit HMG-CoA reductase, the 
rate-limiting enzyme in cholesterol synthesis, disrupts barrier function (Proksch, 
Feingold et al. 1992).  
Cutaneous cholesterol synthesis is virtually autonomous. Although basal cells 
are capable of taking up cholesterol from the circulation, cholesterol synthesis in 
the upper layers is influenced neither by dietary cholesterol nor by circulating 
cholesterol levels (Proksch, Elias et al. 1990). The autonomy is due to the 
absence of LDL receptors on the plasma membranes of keratinocytes committed 
to differentiation whereas undifferentiated keratinocytes on the basal layer have 
LDL receptors (Williams, Mommaas-Kienhuis et al. 1987, te Pas, Lombardi et al. 
1991). 
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1.3 Vitamin D production, metabolism and function in mammalian skin 
1.3.1 Role of vitamin D in calcium homeostasis 
Vitamin D has been widely known to maintain calcium homeostasis. It either can 
be synthesized in the skin from 7-dehydrocholesterol (7-DHC) upon exposure to 
UV irradiation, or be taken in the diet. Vitamin D in the circulation is bound to 
vitamin D binding protein and is transported to the liver where it is hydroxylated 
at position 25 to form 25-hydroxyvitamin D [25(OH)D3]. 25(OH)D3 is further 
hydroxylated in the kidney by the enzyme CYP27B1 to form 1,25-
dihydroxyvitamin D [1,25(OH)2D3], the most active form of vitamin D and the 
ligand for vitamin D receptor (VDR). 1,25(OH)2D3 acts at the intestine, kidney, 
and bone to regulate blood calcium levels. When there is a need to increase 
blood calcium levels, 1,25(OH)2D3 increases intestinal calcium absorption. If this 
is insufficient, 1,25(OH)2D3 works in concert with parathyroid hormone (PTH) in 
the kidney to promote calcium reabsorption from the distal tubule, and in the 
skeletal system to release calcium from bones. 1,25(OH)2D3 acts through the 
VDR in nucleus of cells in target tissues. The VDR heterodimerizes with the 
retinoid X receptor (RXR), and the VDR/RXR complex binds to VDR-responsive 
elements found in or around target genes, resulting in the transcription of these 
genes (Christakos, Hewison et al. 2013). 
More recently, however, the discovery of the VDR in tissues that have no 
involvement in calcium homeostasis and bone health (e.g., skin, placenta, 
pancreas, breast, prostate and colon cancer cells, and activated T cells) has led 
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to exploration of its broader biological significance (Christakos, Hewison et al. 
2013).  
1.3.2 Regulation of vitamin D production and metabolism in mammalian skin 
1.3.2.1 Regulation of vitamin D production in mammalian skin 
The immediate product of 7-DHC ring-opening after ultraviolet irradiation is 
previtamin D3 (pre-D3) (Holick, Richtand et al. 1979). The formation of pre-D3 is 
rapid and reaches plateau within hours. Subsequently it undergoes a 
temperature-catalyzed rearrangement of the triene structure at 37˚C to form 
vitamin D3, which is also known as cholecalciferol (Bikle 2011). Further irradiation 
increased only the biologically inactive photoisomers, lumisterol and tachysterol 
which are photochemically generated from pre-D3. The generation of these preD3 
metabolites appears to limit preD3 accumulation and vitamin D3 intoxication in 
human skin during excessive exposure to the sun (Holick, MacLaughlin et al. 
1981).  
The spectral character of natural sunlight has a profound effect on the 
photochemistry of 7-DHC in human skin, with the optimum wavelengths for the 
production of preD3 between 295 and 300 nm (MacLaughlin, Anderson et al. 
1982).  
The photoproduction of pre-D3 is not only governed by UV light, but more 
importantly, by the availability of 7-DHC content because skin 7-DHC content is 
entirely derived from biosynthesis in the skin, and the highest skin concentrations 
of 7-DHC are found in the epidermis (Esvelt, DeLuca et al. 1980). After exposure 
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to sunlight, the synthesis of pre-D3 reaches a plateau at about 10 to 15 percent of 
the original 7-DHC content in vivo (Holick, MacLaughlin et al. 1981) and 70 
percent in vitro (Nemanic, Whitney et al. 1983). 7-DHC levels can be modulated 
by calcium, hydrocortisone, EGF, and 1,25(OH)2D3 in the circulation (Esvelt, 
DeLuca et al. 1980, Nemanic, Whitney et al. 1983). Interestingly, the production 
of 7-DHC is 5-8 times greater than the production of desmosterol, the final 
intermediate in the alternative ∆24 reductase pathway of cholesterol synthesis 
(Herman 2003). As human keratinocytes show a preferential utilization of the ∆7-
reductase vs. ∆24 pathway, the ∆7-reductase may be the rate-limiting enzyme in 
post-lanosterol cholesterol biosynthesis in the epidermis. Thus, the ∆7-reductase 
may serve as a control point for both cholesterologenesis and vitamin D3 
generation in the skin (Nemanic, Whitney et al. 1983). 
1.3.2.2 Metabolism of vitamin D3 to its biologically active products 
The epidermis is not merely the site of vitamin D3 photoproduction. Epidermal 
keratinocytes are the only cells in the body which possess the complete vitamin 
D signaling pathway, including the VDR, the 25-hydroxylase (CYP27A1) and the 
1α-hydroxylase (CYP27B1), allowing these cells to generate the active VDR 
ligand, 1,25(OH)2D3. The production of 1,25(OH)2D3 in the skin could serve not 
only a local need in regulating the unique epidermal functions of vitamin D 
production and keratin synthesis, but also a systemic need in times of reduced 
production of 1,25(OH)2D3 by the kidney (Bikle, Nemanic et al. 1986, Vantieghem, 
Kissmeyer et al. 2006, Bikle 2011).  
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1,25(OH)2D3 negatively regulates its own levels within the keratinocyte. This 
feedback inhibition is due to induction of 25(OH)D 24-hydroxylase (CYP24A) that 
converts 25(OH)D3 and 1,25(OH)2D3 to 24,25(OH)2D3 and 1,24,25(OH)3D3, 
respectively (Bikle 2011). The increased production of 24,25(OH)2D3 as 
1,25(OH)2D3 production declined is correlated with the early events of 
differentiation such as expression of transglutaminase activity and the levels of a 
precursor protein for the cornified envelopes, involucrin (Pillai, Bikle et al. 1988). 
The expression and activity of CYP27B1 also changes with differentiation, with 
the highest expression in the stratum basale in vivo and the greatest enzymatic 
activity in the undifferentiated cells in vitro (Bikle 2011). 
1.3.3 The role of vitamin D in skin cancer 
Since the first observation of the positive correlation between latitude of 
residence and incidence of colon cancer, numerous studies have evaluated the 
potential role of 1,25-dihydroxyvitamin D3 and vitamin D receptor (VDR) for 
anticancer activity (Tang, Xiao et al. 2011, Bikle, Elalieh et al. 2013). Three 
mechanisms have been established to underlie the protective role of vitamin D in 
tumor formation: (1) inhibition of proliferation and promotion of differentiation; (2) 
induction of DNA damage repair resulting from UV radiation; (3) inhibition of 
hedgehog signaling. For the purpose of this dissertation, mechanisms one and 
three will be addressed. 
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1.3.3.1 Vitamin D inhibits proliferation and promotes differentiation of 
keratinocytes 
The unexpected finding of the VDR in the epidermis (Stumpf, Sar et al. 1979) led 
to studies of the role of 1,25(OH)2D3 in the skin. Hosomi et al. made the first 
observation with mouse epidermal cells that 1,25(OH)2D3 induces keratinocyte 
differentiation dose-dependently at concentrations of 0.12 nM or more. The size 
and density of the cells became larger and lighter, respectively, during the course 
of differentiation. 1,25(OH)2D3 also stimulated formation of a cornified envelope. 
(Hosomi, Hosoi et al. 1983). Similar observations of morphologic and 
biochemical differentiation were seen in cultured human epidermal keratinocytes 
grown under defined, serum-free conditions (Smith, Walworth et al. 1986). 
1,25(OH)2D3 also increases the expression of differentiation markers such as 
involucrin, transglutaminase, loricrin, and filaggrin while inhibiting proliferation. 
Mice lacking the VDR or the enzyme (CYP27B1) that produces its ligand, 
1,25(OH)2D3, show defective epidermal differentiation manifesting as reduced 
levels of involucrin and loricrin and loss of keratohyalin granules (Bikle 2011). 
1,25(OH)2D3 at subnanomolar concentrations either promotes or inhibits 
keratinocyte proliferation. Concentrations above 10-9 M are generally found to 
have only an antiproliferative effect which is accompanied by an increase in TGF-
β and a reduction in c-myc and the EGF receptor mRNA levels. The mechanisms 
underlying the proproliferative actions are not known (Bikle, Ng et al. 2001).  
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Interestingly, expression of the VDR is highest in the basal layers (Stumpf, Sar et 
al. 1979) and both the VDR and the production of 1,25(OH)2D3 are reduced in the 
later stages of differentiation indicating a feedback regulation (Bikle, Ng et al. 
2001). 
1.3.3.2 Vitamin D inhibits hedgehog signaling pathway in keratinocytes 
1.3.3.2.1 Hedgehog signaling pathway 
Hedgehog (Hh) proteins comprise a family of secreted signaling molecules 
essential for developmental patterning of structures in animal embryogenesis. 
The 45 kDa hedgehog protein precursor undergoes autocatalytic cleavage 
mediated by its carboxyl-terminal domain to yield a 20 kDa amino-terminal 
fragment (HH-N) responsible for all known Hh signaling activity (Porter, Young et 
al. 1996). The HH-N possesses a covalently linked cholesterol moiety on the 
carboxyl end and is palmitoylated at the amino-terminus. This dual lipid 
modification of the Hh has important effects on its properties, both enhancing its 
membrane association and potentiating its secretion and range of action (Gallet, 
Ruel et al. 2006, Ingham, Nakano et al. 2011). A decreased level of cholesterol 
leads to impaired Hh autoprocessing and diminished responsiveness to the Hh 
signal (Cooper, Wassif et al. 2003). Originally discovered in Drosophila 
melanogaster, three vertebrate homologs of the Hh gene have been identified 
including sonic hedgehog (SHH), desert hedgehog (DHH) and Indian hedgehog 
(IHH) (Bale and Yu 2001). 
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The hedgehog signal is received and transduced at the membrane via a receptor 
complex consisting of patched and smoothened (Bale and Yu 2001). In the 
absence of hedgehog, the function of smoothened is inhibited by patched. When 
hedgehog binds to patched, this inhibition of smoothened is lost resulting in the 
activation of the zinc finger-containing GLI protein family which function as 
transcriptional activators of a variety of genes in the nucleus (Ingham, Nakano et 
al. 2011). 
1.3.3.2.2 Hedgehog signaling in skin cancer 
Hh signaling has a multitude of functions in embryonic and adult tissues, 
mediating fundamental processes such as cell fate specification, proliferation and 
patterning, tissue morphogenesis and homeostasis (Ingham, Nakano et al. 2011). 
On the other hand, it is also identified as a potentially important stimulator of 
carcinogenesis when dysregulated. This can occur via mutations in the genes 
encoding components of the pathway or by excess production of Hh ligand by 
the tumor or stromal cells (Tang, Xiao et al. 2011). For example, germline 
mutations of patched cause Gorlin syndrome, an autosomal dominant disorder 
characterized by multiple skin cancers, other tumors and congenital anomalies of 
the brain, bones and teeth (Bale and Yu 2001).  
Overexpression of Hh in mice can induce the development of basal cell 
carcinoma (BCC), a tumor originating from undifferentiated pluripotent cells in the 
skin (Zhou, Jia et al. 2006). BCC is the most common of all human cancers, 
representing at least one-third of all cancers diagnosed in the US each year 
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(Bale and Yu 2001) and affecting approximately 1 million Americans per year. 
The pivotal molecular abnormality in BCC is constitutive activation of the Hh 
signaling pathway in 10% to 20% of tumors by mutational activation of 
smoothened and in the great majority of the others is associated with mutational 
inactivation of patched1 (Tang, Xiao et al. 2011). The Ptch1+/- mouse developed 
as the first practical model of murine BCC, is quite susceptible to the 
development of BCC following UV radiation (Bikle, Elalieh et al. 2013). 
1.3.3.2.3 Potential roles of vitamin D3 and 7-dehydrocholesterol reductase 
(DHCR7) in hedgehog signaling 
Mice lacking the VDR have constitutively active hedgehog signaling, whereas 
1,25-dihydroxyvitamin D3 can suppress this pathway in normal skin. So loss of 
1,25-dihydroxyvitamin D3 and/or VDR regulation of Hh signaling is one of the 
causes of the increased susceptibility of the epidermis to malignant 
transformation (Bikle, Elalieh et al. 2013). 
The suppression of the Hh pathway occurs not only via the genomic actions of 
1,25-dihydroxyvitamin D3 acting through its receptor, but through the direct 
binding of vitamin D3 to smoothened. Thus, vitamin D3 may potentially serve as a 
chemopreventive and/or chemotherapeutic agent for BCCs (Bijlsma, Spek et al. 
2006, Tang, Xiao et al. 2011, Bikle, Elalieh et al. 2013). 
Interestingly, a defect in (or the absence of) DHCR7 that leads to the 
accumulation of its substrate, 7-DHC, inhibits smoothened activity. AY-9944, an 
inhibitor of DHCR7, also results in the repression of smoothened (Bijlsma, 
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Peppelenbosch et al. 2006). Although not as potent as vitamin D3, 7-DHC directly 
binds to and inhibits the action of smoothened (Bikle, Elalieh et al. 2013). These 
results underline the important role of DHCR7 in keratinocytes to maintain a 
balance between cholesterol and vitamin D3 production. 
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1.4 The potential role of 7-dehydrocholesterol reductase in vitamin D 
deficiency 
7-DHC, the substrate of DHCR7, is also the precursor of vitamin D3. Thus it may 
be of importance to characterize biochemical and genetic aspects of DHCR7 to 
understand and ultimately prevent and treat vitamin D deficiency.  
1.4.1 The biochemical characterizations of human 7-dehydrocholesterol 
reductase 
The human 7-dehydrocholesterol reductase (DHCR7) gene is on chromosome 
11q13 (Fitzky, Witsch-Baumgartner et al. 1998) and the mRNA is ubiquitously 
transcribed but most abundant in adrenal gland, liver, testis, and brain. Human 
DHCR7 enzyme is a membrane-bound protein with a predicted molecular mass 
of 55 kDa and six to nine putative transmembrane segments with the N terminus 
oriented toward the cytosol (Fitzky, Witsch-Baumgartner et al. 1998, Moebius, 
Fitzky et al. 1998). 
7-Dehydrocholesterol reductase (DHCR7) catalyzes the final step in cholesterol 
synthesis on the smooth endoplasmic reticulum, reducing the C (7-8) double 
bond in 7-dehydrocholesterol (7DHC) by using NADPH as the electron donor. 
Substrate specificity assays indicate that the reduction of the double bond at C-
7,8 requires binding of the enzyme protein with the B-ring of the sterol substrate 
that contains a double bond at C-5,6 and that the reaction is hindered by 
substituents located on the apolar side-chain and epimerization of the hydroxyl 
group in ring A to a 3α-configuration. The enzymatic activity is increased by 
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phosphorylation and inhibited by AY9944 (IC50 0.013 µM), BM15766 (IC50 1.2 µM) 
and triparanol (IC50 14 µM) (Moebius, Fitzky et al. 1998, Shefer, Salen et al. 
1998). The expression of the DHCR7 gene is directly activated by the 
transcription factor SREBP-2, dedicated to the synthesis of cholesterol (Horton, 
Goldstein et al. 2002). Some antipsychotic drugs such as clozapine, 
chlorpromazine, and haloperidol and antidepressants such as imipramine are 
able to induce the transcription of DHCR7 gene by activating the SREBPs (Lauth, 
Rohnalter et al. 2010). 
A distinguishing characteristic of DHCR7 is the presence of the sterol-sensing 
domain (SSD) attributed to its role in cholesterol homeostasis and cholesterol-
linked signaling. It is increasingly appreciated that cholesterol has the potential to 
affect organismal development, thus deficiency of DHCR7 has been shown to be 
responsible for causing developmental malformations (Kuwabara and Labouesse 
2002). Smith-Lemli-Optiz Syndrome (SLOS), which is an autosomal recessive 
disease, is caused by a defect of the enzyme DHCR7 and consequently low 
serum cholesterol levels. The clinical spectrum of SLOS includes different 
morphogenic abnormalities such as limb/skeletal and urogenital anomalies, 
growth and mental retardation, as well as failure to thrive and behavioral 
problems (Jira, Waterham et al. 2003).  
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1.4.2 The genetic variations of 7-dehydrocholesterol reductase in vitamin D 
deficiency 
25-Hydroxyvitamin D, the primary circulating form of vitamin D, is used to 
determine a person’s vitamin D status and a level less than 20 ng per milliliter is 
defined as vitamin D deficiency (Holick 2007). Genome-wide association study 
(GWAS) of 25-hydroxyvitamin D suggested that single-nucleotide polymorphisms 
(SNPs) in or near genes involved in vitamin D synthesis or activation are 
associated with low 25-hydroxyvitamin D level and elevated risk of vitamin D 
deficiency. In both European and Chinese populations, the variants of genes 
involved in vitamin D transport (GC), hydroxylation (CYP2R1, CYP24A1), and 
interestingly, cholesterol synthesis (DHCR7) are suggestive to influence plasma 
25-hydroxyvitamin D status (Ahn, Yu et al. 2010, Wang, Zhang et al. 2010, Lu, 
Sheng et al. 2012).  
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Chapter 2: Experimental rationale 
Both cholesterol and vitamin D3 are indispensable for the proper function of skin. 
DHCR7 activity likely influences skin 7-DHC content available for both 
cholesterologenesis and vitamin D3 photosynthesis. It was suggested that the 
photoproduction of vitamin D3 is not only governed by UV light, but more 
importantly, by the availability of 7-DHC, which is entirely derived from 
biosynthesis in the skin (Esvelt, DeLuca et al. 1980). I hypothesized that as 
vitamin D3 accumulated it might promote the activation of DHCR7 to limit further 
vitamin D3 production by increasing the conversion of 7-DHC to cholesterol, 
thereby depleting 7-DHC levels in the keratinocyte.  Alternatively, vitamin D3 
might enhance its own production by suppressing DHCR7 activity, thereby 
making more 7-DHC available for photoconversion to vitamin D3.  It has been 
established that DHCR7 could be activated by phosphorylation and inactivated 
by dephosphorylation (Shefer, Salen et al. 1998), and so I wished to determine if 
vitamin D3 regulated DHCR7 activity by these mechanisms. Direct inhibition by 
vitamin D or allosteric modulation of enzyme activity was also considered. More 
long-term regulation, through changes in enzyme levels mediated by increased 
or decreased gene expression and protein stability were also evaluated. The 
involvement of the vitamin D receptor in the regulation of DHCR7 by vitamin D3 
was to be determined since it regulates the transcription of numerous genes in 
skin and other tissues (Bikle 2011). The effect of UVB irradiation on DHCR7 
activity in keratinocyte cells was examined based on the supposition that 7-DHC 
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in keratinocytes would be converted into vitamin D3. The effect of vitamin D3 on 
cholesterolgenesis was also investigated. 
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Specific Aims 
Specific Aim 1: Determine if vitamin D3, 25-hydroxyvitamin D3, 1,25-
dihydroxyvitamin D3, and UV light modulate the activity and expression of 
DHCR7 in whole cells. This aim had two parts: 1) to determine if different forms 
of vitamin D regulate DHCR7 activity; 2) to determine if the response of DHCR7 
to vitamin D is specific to keratinocytes. Rat hepatoma (McA-RH7777), human 
hepatoma (HepG2), human immortal keratinocyte (HaCaT), and adult human 
epidermal keratinocyte (HEKa) cells would be cultured and treated with different 
forms of vitamin D. Only HEKa cells would be exposed to UV light, which 
provides an alternative way to generate vitamin D3, to test the effect of UVB on 
DHCR7 activity in keratinocytes.  
Specific Aim 2: Determine the mechanism by which vitamin D regulates DHCR7 
activity. Possible mechanisms include: 1) phosphorylation/dephosphorylation; 2) 
transcriptional regulation by the vitamin D receptor (VDR); 3) direct binding of 
vitamin D3 to DHCR7, either as an inhibitor or as an allosteric modulator; and 4) 
signaling through the hedgehog pathway to modulate DHCR7 activity. It has 
been shown that addition of ATP to rat microsomes increases DHCR7 activity 
and phosphatase treatment prevents this activation and decreases DHCR7 
activity. The effect of ATP on DHCR7 activity would be determined in mouse 
microsomes, McA-RH7777 cells, HepG2 cells, HaCaT cells and HEKa cells. If 
confirmed in HEKa cells, I would attempt to identify the protein kinase involved. 
The response of DHCR7 to 1,25-dihydroxyvitamin D3 would be used to determine 
if the vitamin D receptor is involved in the regulation of DHCR7. The ability of 
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vitamin D3 to modulate DHCR7 activity when added directly to cell lysates would 
also be determined. To evaluate the role of the hedgehog signaling pathway in 
vitamin D regulation of cell differentiation and DHCR7 activity, I would determine 
if vitamin D3 and cyclopamine, an inhibitor of hedgehog signaling, inhibit 
proliferation, induce differentiation of HEKa cells, and affect DHCR7 activity. 
Specific Aim 3: Determine if vitamin D3 affects other enzymes in the 
cholesterologenic pathway. Changes in the activity of the pre-sterol synthesis 
steps would be evaluated by treating the cells with a lanosterol demethylase 
inhibitor (ketoconazole) and then measuring lanosterol accumulation in vitamin 
D3-treated and untreated cells. The effect of vitamin D3 treatment on the activity 
of lathosterol 5-desaturase, the enzyme that immediately precedes DHCR7 in the 
cholesterolgenic pathway, would be measured directly. 
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Chapter 3: Materials and methods 
List of Chemicals, Buffers, and Reagents 
Chemicals 
The following chemicals were used in these studies and were purchased from 
standard suppliers: Dipotassium phosphate (K2HPO4), dithiothreitol (DTT), 
nicotinamide, ethylenediaminetetraacetic acid (EDTA), nicotinamide adenine 
dinucleotide phosphate (NADP+), glucose-6-phosphate, glucose-6-phosphate 
dehydrogenase, sodium hydroxide, adenosine-5’-triphosphate (ATP), 
magnesium chloride (MgCl2), methyl-β-cyclodextrin (MβCD), 
ergosterol (2.5 mM stock in 13% MβCD), brassicasterol, stigmasterol (dissolved 
in ethanol), cholecalciferol (dissolved in ethanol), 7-dehydrocholesterol (in 13% 
MβCD), cholesterol, lanosterol, lathosterol (dissolved in 13% MβCD), 25-
hydroxycholecalciferol (dissolved in ethanol), 1,25-dihydroxyvitamin D (dissolved 
in ethanol), 
ethanol, isobutanol, and hexanes. 
Buffers and solutions 
Ethanolic NaOH solution: 1 M NaOH, 70% ethanol 
Lower Tris Buffer: 1.5 M Tris base, 0.4% w/v SDS, pH 8.8 
Upper Tris Buffer: 0.5 M Tris base, 0.4% w/v SDS, pH 6.8 
5X Running Buffer: 125 mM Tris base, 1 M Glycine, 0.5% w/v SDS 
 32 
 
1X Electroblot Transfer (ET) Buffer: 25 mM Tris base, 200 mM Glycine, 0.1% w/v 
SDS, 20% methanol 
10X TBS: 200 mM Tris base, 1.37 M NaCl, pH 7.6 
TBST (Wash Buffer): 1X TBS, 0.2% Tween 20 
Blocking Buffer: 5% w/v Bovine Serum Albumin 
9% resolving gel for 3 SDS-PAGE gels: 7.5 ml of lower Tris, 8.8 ml of 30% Acyl-
bis, 12.3 ml of ddH2O, 450 µl of 10% APS, 15 µl of TEMED 
3.3% stacking gel for 3 SDS-PAGE gels: 2.5 ml of upper Tris, 1.1 ml of 30% 
Acyl-bis, 6.2 ml of ddH2O, 150 µl of 10% APS, 20 µl of TEMED 
4X SDS-PAGE sample loading buffer (10 ml): 2.4 ml of 1 M Tris-Hcl (pH 6.8), 
0.8g of SDS, 4.0 ml of 100% glycerol, 0.5 ml of β-mercaptoethanol, 4.0 mg of 
bromophenol blue, 3.1 ml of H2O.    
Hepatoma or HaCaT cell culture (1 L): 13.4 g of Dulbecco’s Modified Eagle’s 
Medium (DMEM) powder, 3.7 g of sodium bicarbonate, ddH2O, pH 7.3. Filter to 
sterilize. Supplement with 10% fetal bovine serum and 1% penicillin-streptomycin. 
HEKa cell culture: EpiLife medium, Human Keratinocyte Growth Supplement.  
Trypsin/EDTA, Defined trypsin neutralizer 
Dulbecco’s phosphate-buffered saline (DPBS) 
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Reagents 
HaltTM protease inhibitor cocktail, PhosSTOP phosphatase inhibitor cocktail 
tablets, 
M-PER® mammalian protein extraction reagent (Thermo Scientific), 
PierceTM BCA protein assay kit, 
TRIzol® reagent. 
Table 3.1: Primary antibodies used in this dissertation: 
Host Primary Antibodies Dilution Supplier 
Rabbit DHCR7 WB 1:500 Sigma, Cat. No: D7695 
Mouse Involucrin WB 1:1000 Sigma, Cat. No: I9018 
Mouse β-actin WB 1:5000 Sigma, Cat. No: A1978 
Table 3.2: Secondary antibodies used in this dissertation: 
Secondary Antibodies Dilution Supplier 
ECL Plex goat-α-rabbit lgG-Cy3 1:2500 GE Healthcare, Cat. No: 
28901106 
ECL Plex goat-α-mouse lgG-Cy5 1:2500 GE Healthcare, Cat. No: 
PA45009 
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Cell Culture 
HEKa cells between passages 1 to 5 were cultured in EpiLife medium (GIBCO) 
supplemented with EpiLife Defined Growth Supplement (EDGS) in 100 mm cell 
culture plate at 37°C under a humidified atmosphere of 5% CO2. The culture 
medium was changed after 36 hours and every other day thereafter, until the 
cultures were approximately 50% confluent, after which the medium was 
changed every day until the culture was approximately 80% confluent. Chemicals 
were added according to experimental design.  
McA-RH7777 rat hepatoma cells, HepG2 human hepatoma cells, and HaCaT 
human keratinocyte cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(Gibco) supplemented with 10% fetal bovine serum and 1% penicillin-
streptomycin (Invitrogen) in 100 mm cell culture plates at 37°C under a 
humidified atmosphere of 5% CO2. The culture medium was changed every 2 
days. Chemicals were added according to experimental design. 
Preparation of lysates: Cells were washed twice with ice cold Dulbecco’s 
phosphate-buffered saline (GIBCO) and scraped from the plates, pelleted by 
centrifugation (200 x g for 10 minutes) and lysed with M-PER mammalian protein 
extraction reagent (Thermo Sientific) supplemented with 1x protease and 
phosphatase inhibitors on ice for 30 minutes. The lysates were cleared by 
centrifugation (18,300 x g, 4°C for 10 minutes) and the supernatant was used 
immediately. 
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Activity Assays 
Microsomal/Cell Lysate 7-Dehydrocholesterol Reductase Activity Assay 
Microsomal or lysate protein was incubated in a final volume of 0.5 ml (pH 7.3) 
containing 100 µg microsomal/cell lysate protein, 60 μM ergosterol, 100 mM 
K2HPO4, 1 mM DTT, 0.1 mM EDTA, 30 mM nicotinamide, and an NADPH-
generating system (3.4 mM NADP+, 30 mM glucose-6-phosphate, 0.3 IU 
glucose-6-phosphate dehydrogenase); in some experiments, 50 mM ATP and 50 
mM MgCl2 were included. After incubation at 37˚C for various time-periods, the 
reaction was stopped by the addition of 1 ml of 1 M ethanolic NaOH and the 
mixture was allowed to stand for 1 h at 37˚C. After adding 0.5 ml water, the 
products were extracted twice with 2 ml of hexanes which subsequently were 
evaporated under nitrogen. Extracts were derivatized, identified, and quantified 
by GC/MS at the UK Mass Spectrometry facility, focusing on mass ions 363 
(ergosterol), 380 (brassicasterol), and 394 (stigmasterol, internal standard). 
DHCR7 activity was interpreted as the ratio of brassicasterol/stigmasterol. 
Intact Cell 7-Dehydrocholesterol Reductase Activity Assay 
Ergosterol (60 µM) dissolved in methyl-β-cyclodextrin was added to the cell 
culture medium and the cells were incubated in a 37°C, 5% CO2/95% air, 
humidified cell culture incubator for designated times according to experimental 
design. Stigmasterol (1 µg) was added to the cell culture medium before 
harvesting the cells with 2 ml of ethanolic NaOH. The cell culture medium and 
harvested cells were extracted with hexanes. After centrifugation, the 
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supernatant was evaporated and analyzed by GC/MS at the UK Mass 
Spectrometry facility, focusing on mass ions 363 (ergosterol), 380 
(brassicasterol), and 394 (stigmasterol, internal standard). DHCR7 activity was 
interpreted as the ratio of brassicasterol/stigmasterol. 
Lathosterol-5-Desaturase Activity Assay 
Reaction mixtures were prepared by combining 100 mM K2HPO4, 1 mM DTT, 
100 µM EDTA, 100 µM lathosterol, 100 µg lysate protein, and 2.5 mM NADH. 
Samples were assayed as described in the cell lysate 7-dehydrocholesterol 
reductase activity assay. 
GC/MS Sample Analysis by Wsearch32 
Compounds were identified by specific mass-to-charge ratio (m/z) and quantified 
as the integrated area of the peak of m/z at the specific retention time. 7-
Dehydrocholesterol reductase activity was calculated as the Peak Area of 
Brassicasterol/Peak Area of Stigmasterol. Lathosterol-5-desaturase activity was 
measured as the Peak Area of 7-Dehydrocholesterol/Peak Area of Stigmasterol. 
Lanosterol accumulation was measured as the Peak Area of Lanosterol/Peak 
Area of Stigmasterol. 
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Table 3.3: Compound mass-to-charge ratio (m/z) and retention time  
Compound m/z Retention Time (min)* 
7-Dehydrocholesterol 351 24.20 
Cholesterol 368 23.60 
Cholecalciferol 351 21.63 
25-Hydroxycholecalciferol 341 24.13 
1,25-Dihydroxyvitamin D3 343 25.90 
Lanosterol 393 25.78 
Lathosterol 353 24.30 
Brassicasterol 380 24.16 
Ergosterol 363 24.68 
Stigmasterol 394 25.28 
*Retention time may vary based on the adjustment of the GC/MS machine. 
UVB Irradiation 
HEKa cells were exposed to UVB irradiation after reaching 80% confluence. 
Cells were washed with DPBS before exposure. The cell culture plate was 
placed in the Lucite chamber with the cover on the plate. Exposure to UVB was 
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for sufficient time to receive desired dosing (100 J/m2 and 200 J/m2). Cell culture 
medium was added back to cells immediately after the irradiation and incubation 
continued in a 37°C, 5% CO2/95% air, humidified cell culture incubator for 3 
hours or 24 hours according to experimental design. 
Gel electrophoresis and immunoblotting 
Fifty micrograms of cell lysate protein was fractionated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis on 8% gels and electroblotted to 
nitrocellulose sheets. The membrane was blocked with Blocking Buffer for 30 
minutes at room temperature and then incubated overnight at 4°C in buffer mixed 
with Wash Buffer and Blocking Buffer (4:1) containing primary antibody to 
DHCR7, involucrin, or β-actin. The immunoblot was developed with Cy3- or Cy5-
conjugated secondary antibody at room temperature for 1.5 hours while being 
protected from light. The fluorescent blot was then scanned on the Typhoon FLA 
9000 Scanner and quantitatively analyzed by the ImageQuant software. 
RT-PCR 
RNA isolation 
Total RNA was isolated from cells with the use of TRIzol reagent. The 
concentration of total RNA was determined with the use of the Nanodrop 
instrument. 
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Reverse Transcriptase reaction 
In a nuclease-free tube, 200 ng of random primers was added along with 1 µl of 
dNTP mix (10 mM each nucleotide), 200 ng total RNA in a total volume of 12 µl 
in diethylpyrocarbonate-treated water. The mixture was heated to 65°C for 5 
minutes and quickly chilled on ice. The mixture was collected by brief 
centrifugation and 4 µl of 5x First-Strand Buffer, 1 µl of SuperScript II Reverse 
Transcriptase, 2 µl of 0.1 M DTT, and 1 µl of RNase OUT was added. The 
reaction was incubated at 25°C for 10 minutes, followed by 50 minutes at 42°C 
and inactivated by incubation at 70°C for 15 minutes. The synthesized cDNA was 
aliquoted and stored at -20°C. 
Real-time PCR 
Gene-specific primers for real-time PCR were designed using Primer 3 software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The sequences of the primers 
are shown in Table 3.4. The concentrated cDNA template was diluted 6-fold in a 
1:5 serial dilution to achieve the final concentration used in the PCR reaction. 
Each 20 µl of PCR reaction mixture contained 5 µl of diluted cDNA template, 10 
µl of 2x SYBR Green PCR Master Mix, 0.4 µl of Forward Primer (100 nM final), 
0.4 µl of Reverse Primer (100 nM final), and 4.2 µl of nuclease-free water. The 
plate was sealed thoroughly to prevent evaporation. PCR was carried out in the 
7900HT thermal cycler as follows: Cycling conditions were 2 minutes at 50°C to 
activate, initial denaturation for 10 minutes at 95°C, followed by 40 cycles of 
denaturation for 15 seconds at 95°C and 1 minute of annealing/extension at 60°C. 
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The detection and quantitation of target gene expression levels was done by 
using the comparative CT method. 
Table 3.4: Primer sequence for gene expression 
Abbreviation Gene 
Name 
Accession 
Number 
Forward/Reverse primers 
DHCR7 7-
Dehydroch
olesterol 
reductase 
NM_001163817.1 Fw 
GCAACCCAACATTCCCAAAG 
Rv 
TCGCCAGTGAAAACCAGTC 
GAPDH Glyceralde
hyde-3-
phosphate 
dehydroge
nase 
NM_002046.4 Fw 
ACATCGCTCAGACACCATG 
Rv 
TGTAGTTGAGGTCAATCAAGGG 
 
 
 
 
Copyright © Ling Zou 2013 
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CHAPTER FOUR: Results 
Vitamin D3 decreases 7-dehydrocholesterol reductase activity in adult 
human epidermal keratinocytes 
7-Dehydrocholesterol (7-DHC) is the substrate of 7-dehydrocholesterol reductase 
(DHCR7) for cholesterol synthesis. Keratinocytes in human skin possess the 
machinery for cholesterol synthesis and are also responsible for vitamin D3 
synthesis from 7-DHC by exposure to UVB irradiation. Therefore, it is important 
for keratinocytes to maintain a balance between cholesterol synthesis, which 
forms an important component of the skin barrier function, and vitamin D3 
production. A recent genome-wide association study (GWAS) suggested that 
SNPs in DHCR7 are associated with vitamin D deficiency (Ahn, Yu et al. 2010). 
This provides us with an insight into understanding the regulation of vitamin D3 
synthesis in skin and a potential target for drug therapy. In order to pursue this 
goal, we first asked whether DHCR7 responds to vitamin D3 treatment. 
Hypothetically, vitamin D3 could increase DHCR7 activity, favoring cholesterol 
synthesis, through a feedback mechanism so as to decrease 7-DHC content in 
keratinocytes against further vitamin D3 production. To test this hypothesis, adult 
human epidermal keratinocytes (HEKa) were used to measure the DHCR7 
response to vitamin D3 treatment in HEKa cell lysates and in intact cells. 
Unexpectedly, vitamin D3 decreased DHCR7 activity to 85% and 35% compared 
to control after 3 hour treatment at 1 µM and 10 µM concentrations, respectively 
(Fig 4.1A). The decrease in activity was evident as early as 2 hours after vitamin 
D3 treatment of whole cells when measured with keratinocyte lysates (Fig 4.1B). 
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Interestingly, DHCR7 is more sensitive to vitamin D3 in intact cells as the activity 
decreased more than that in cell lysates (67% and 19% at 1µM and 10µM 
concentrations, respectively) (Fig 4.1C) and continuously decreased from 96% 
(after 10 minute treatment) to 22% (after 180 minute treatment) compared to 
control (Fig 4.1D). This rapid down-regulation of DHCR7 activity by vitamin D3 is 
at the post-translational level as I saw no change in the amount of DHCR7 
protein over the course of the treatment (Fig 4.1G). In comparison to this 
immediate effect after short-term (3 h) treatment, long-term (up to 48 h) treatment 
of HEKa cells with 10 µM of vitamin D3 suppressed DHCR7 activity nearly 
completely (Fig 4.1E). Recovery from even a short treatment with vitamin D3 was 
slow, with DHCR7 activity returning to about 60% of its original levels at 24 h (Fig 
4.1F).   
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Figure 4.1: Vitamin D3 decreases 7-dehydrocholesterol reductase activity in 
HEKa cells. Measurement of DHCR7 activity in cell lysates (A and B) and in 
intact cells (C and D) after vitamin D3 treatment (3 h) at various concentrations (A 
and C) and after 10 µM of vitamin D3 treatment at various time points (B and D). 
E, Measurement of DHCR7 activity in intact cells after continuous treatment with 
10 µM of vitamin D3 and the restoration of DHCR7 activity after discontinuation of 
treatment (F). G, protein expression was measured at various time points after 
treatment of cells with 10 µM of vitamin D3 by immunoblot analysis. Values 
represent the mean and S.D. of 3 or more experiments; values that are 
statistically different from the control are indicated by asterisks, as determined by 
t-test or one-way ANOVA analysis of variance with Dunnett’s multiple 
comparisons post hoc test, p < 0.05. 
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Vitamin D3 has no effect on DHCR7 activities in McA-RH7777, HepG2, and 
HaCaT cells 
Because skin is the only site of vitamin D3 production, it is not necessary for other 
organs, especially the liver, to maintain a balance between cholesterol and 
vitamin D3 production. This leads to the rationale that vitamin D3 should only 
regulate DHCR7 activity in the skin. Therefore, rat hepatoma (McA-RH7777) and 
human hepatoma (HepG2) were used to test this hypothesis. As expected, 
neither of these cell lines responded to a 3-h, 10 µM vitamin D3 treatment (Fig 
4.2A and B). For comparison, immortalized human keratinocytes (HaCaT cells) 
were also tested for their ability to regulate DHCR7 activity in response to vitamin 
D3. Surprisingly, vitamin D3 had no effect on DHCR7 activity in this immortalized 
skin cell line (Fig 4.2C), nor did it change DHCR7 mRNA levels (Fig 4.2D). These 
observations indicate that the regulation of DHCR7 activity by vitamin D3 is 
restricted to normal keratinocytes. During these studies I noted that DHCR7 
protein levels in HepG2 cells were 7-fold greater than that in HEKa cells (Fig 
4.2E) while its activity was just 50% of that in HEKa cells (Fig 4.2F). This 
suggests that DHCR7 activity may be regulated post-translationally in this liver 
cell line by means other than vitamin D3 levels. 
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Figure 4.2 Vitamin D3 has no effect on DHCR7 activities in McA-RH7777, HepG2, 
and HaCaT cells. Activity was measured in cell lysates after a 3-h treatment with 
vitamin D3 (A, B, and C). DHCR7 mRNA levels were measured in HaCaT cells 
after a 24-h treatment with vitamin D3 at various concentrations (D). DHCR7 
protein expression was measured in four cell lines and in mouse microsomes (E). 
The DHCR7 activities in HEKa and HepG2 were measured and compared to 
each other (F). Values represent the mean and S.D. of 3 experiments; values 
that are statistically different from the control are indicated by asterisks, as 
determined by t-test or one-way ANOVA analysis of variance with Dunnett’s 
multiple comparisons post hoc test, p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 48 
 
Effects of 25-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 on DHCR7 
activity in HEKa and HaCaT cells 
After being formed in keratinocytes, vitamin D3 binds to vitamin D binding protein 
in the blood and is subsequently hydroxylated to form 25-hydroxyvitamin D3 and 
then 1α,25-dihydroxyvitamin D3 in the liver and the kidney, respectively. 
Keratinocytes also possess the enzymes necessary to synthesize 25-
hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3. More importantly, the receptor 
for 1α,25-dihydroxyvitamin D3, the vitamin D receptor (VDR), is expressed in 
keratinocytes and has been suggested to be involved in cancer prevention (Bikle, 
Elalieh et al. 2013). The 25-hydroxylated form of vitamin D3 is less inhibitory to 
DHCR7 than is vitamin D3 in HEKa cells, decreasing activity to approximately 30% 
of control levels after 6 h treatment (Fig 4.3A). 1α,25-Dihydroxyvitamin D3 had no 
effect on DHCR7 activity in HEKa and HaCaT cells (Fig 4.3B&D).This is further 
supported by the observation that neither 25-hydroxyvitamin D3 nor a metabolite 
of 25-hydroxyvitamin D3 was synthesized in vitamin D3-treated HEKa cells (Fig 
4.3E). On the other hand, vitamin D3 levels decreased by half 10 minutes after 
addition to HEKa cell culture (Fig 4.3C). This significant decrease in vitamin D3 
content was more rapid than that of DHCR7 activity, suggesting the involvement 
of metabolite(s) of vitamin D3, other than 25-hydroxyvitamin D3 or 1α,25-
dihydroxyvitamin D3, in the regulation of DHCR7 activity.    
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Figure 4.3 Effect of 25-Hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 on 
DHCR7 activity in HEKa and HaCaT cells. DHCR7 activity was measured in 
intact HEKa cells after treatment with 25-hydroxyvitamin D3 (A) or 1α,25-
dihydroxyvitamin D3 (B) at various concentrations and time points. The rate of 
decrease in vitamin D3 content is compared to that of DHCR7 activity after 
vitamin D3 treatment (C). Gas chromatographic profiles of HEKa untreated and 
cells treated with vitamin D3 or 25-hydroxyvitamin D3 is shown (E). Values 
represent the mean and S.D. of 3 or more experiments; values that are 
statistically different from the control are indicated by asterisks, as determined by 
one-way ANOVA analysis of variance with Dunnett’s multiple comparisons post 
hoc test, p < 0.05. 
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Vitamin D3 does not change lanosterol and 7-dehydrocholesterol content in 
HEKa cells 
7-Dehydrocholesterol (7DHC) is the precursor for both cholesterol and vitamin D3 
synthesis. Given that vitamin D3 decreased DHCR7 activity, I anticipated that 
7DHC would accumulate in keratinocytes treated with vitamin D3. Unexpectedly, 
7DHC content did not change after vitamin D3 pre-treatment (Fig 4.4D). There 
was also no change in the activity of lathosterol 5-desaturase which catalyzes the 
conversion of lathosterol to 7DHC, the step that immediately precedes DHCR7 
(Fig 4.4C). Lanosterol, the first intermediate containing the core steroid structure, 
is formed further upstream in the cholesterol synthesis pathway. The inhibition of 
lanosterol 14-demethylase by ketoconazole provided a way to examine changes 
in the early steps in the cholesterol synthesis pathway after vitamin D3 treatment. 
The content of lanosterol in HEKa cells was not changed significantly after short-
term (3 hour) or long-term (24h) treatment with vitamin D3, although there was a 
trend toward a decrease in the content of this vitamin D and cholesterol 
precursor (Fig 4.4A&B). This indicates that vitamin D3 may suppress the early 
steps in the cholesterol/vitamin D3 synthesis pathway.  
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Figure 4.4 Vitamin D3 does not change lanosterol and 7-dehydrocholesterol 
content in HEKa cells. Cells were treated with 10 µM of vitamin D3 for 3 hours 
and then incubated with 10 µM of ketoconazole for 3 hours (A) or 24 hours (B) 
and the accumulated lanosterol was measured. Lathosterol activity was 
measured as the conversion of lathosterol to 7DHC (C). The content of 7DHC 
was measured in HEKa cells untreated or treated with vitamin D3 (D). Values 
represent the mean and S.D. of 3-5 experiments; values that are statistically 
different from the control are indicated by asterisks, as determined by t test 
analysis, p < 0.05. 
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UVB irradiation does not affect DHCR7 activity 
When keratinocytes are exposed to UVB irradiation 7DHC in these cells is 
converted into vitamin D3. Therefore, it is possible that DHCR7 may be regulated 
by UVB irradiation through the product vitamin D3. However, changes in DHCR7 
activity following UVB irradiation were not observed (Fig 4.5A&B).  
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Figure 4.5 UVB does not regulate DHCR7 activity. HEKa cells were exposed to 
UVB with two dosings: 100 J/m2 and 200 J/m2. After exposure, cells were 
cultured for another 3 hours (A) or 24 hours (B) and DHCR7 activity was 
measured. Values represent the mean and S.D. of 3-4 experiments; values that 
are statistically different from the control are indicated by asterisks, as 
determined by one-way ANOVA analysis of variance with Dunnett’s multiple 
comparisons post hoc test, p < 0.05. 
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Regulation of DHCR7 activity by vitamin D3 is not due to 
phosphorylation/dephosphorylation 
Shefer et al. (Shefer, Salen et al. 1998) demonstrated that DHCR7 in rat liver can 
be activated by phosphorylation and inactivated by dephosphorylation. I was able 
to confirm the activation of DHCR7 by ATP in mouse microsomes (Fig 4.6A) and 
rat hepatoma cell lysates (Fig 4.6B), but not in human hepatoma cell lysates (Fig 
4.6C) or in human HaCaT cell lysates (Fig 4.6D). Moreover, neither ATP nor 
protein phosphatase 1 changed DHCR7 activity in cell lysates from both non-
treated and vitamin D3-treated human HEKa cells (Fig 4.6E), suggesting that the 
reduction of DHCR7 activity by vitamin D3 is not due to dephosphorylation. These 
results also suggest that the response of DHCR7 to ATP may be species-
dependent. 
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Figure 4.6 Modulation of DHCR7 activity by vitamin D3 is not due to changes in 
the phosphorylation state of the enzyme. Measurement of DHCR7 activity in 
mouse microsomes (A), rat hepatoma (B), human hepatoma (C), human HaCaT 
(D), and human HEKa (E) cell lysates. ATP or phosphatases were added to cell 
lysates (C & E). Values represent the mean and S.D. of 3 or more experiments; 
values that are statistically different from the control are indicated by asterisks, as 
determined by t-test or one-way ANOVA analysis of variance with Dunnett’s 
multiple comparisons post hoc test, p < 0.05. 
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Regulation of DHCR7 activity by vitamin D3 is not due to direct binding of 
vitamin D3 to DHCR7 in HEKa cells 
Instead of treating HEKa cells in culture with vitamin D3, vitamin D3 was added to 
cell lysates. By this means I could determine if vitamin D3 directly inactivates 
DHCR7 and thereby provide a possible mechanism by which vitamin D3 down-
regulates DHCR7 activity. The reaction was initiated either immediately after 
vitamin D3 addition to the cell lysate or after a 3-hour incubation of the lysate with 
vitamin D3. The activity of DHCR7 did not change in the presence of low and high 
concentrations of vitamin D3 or after pre-incubation with a low concentration of 
vitamin D3 (Fig 4.7). The pre-incubation with 100 µM of vitamin D3 decreased 
DHCR7 activity significantly. However, this concentration is far beyond the 
physiologic concentration, so even though vitamin D3 decreased DHCR7 activity, 
this is not the likely mechanism by which vitamin D3 regulates DHCR7 activity in 
HEKa cells. 
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Figure 4.7 Vitamin D3 did not inhibit DHCR7 in HEKa cell lysates. DHCR7 activity 
was measured immediately after the addition of vitamin D3 to HEKa cell lysates 
or after a 3 hour pre-incubation with vitamin D3 at 37°C. Values represent the 
mean and S.D. of 3 or more experiments; values that are statistically different 
from the control are indicated by asterisks, as determined by one-way ANOVA 
analysis of variance with Dunnett’s multiple comparisons post hoc test, p < 0.05. 
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Vitamin D3 inhibits proliferation and induces differentiation of HEKa cells 
During the long-term treatment of HEKa cells with vitamin D3, the cells gradually 
became elongated and flat, and grew slowly (Fig 4.8B). It has been reported that 
vitamin D induces cell differentiation (Bikle, Ng et al. 2001) and inhibits 
proliferation in basal cell carcinomas (Tang, Xiao et al. 2011). The anti-
proliferative and pro-differentiating effects of vitamin D3 were determined with 
HEKa cells. After 48 hour treatment, 10 µM vitamin D3 (Fig 4.8B), 10 µM 25-
hydroxyvitamin D3 (Fig 4.8D), and 100 nM 1,25-dihydroxyvitamin D3 (Fig 4.8F) 
significantly inhibited the growth of HEKa cells. In contrast, 10 µM 7-DHC (Fig 
4.8C), 10 nM 1,25-dihydroxyvitamin D3 (Fig 4.8E) and 10 µM cholesterol (Fig 
4.8G) did not have antiproliferative effects on HEKa cells. Vitamin D3 induced 
expression of involucrin, a marker of cell differentiation (Fig 4.9A). Interestingly, 
25-hydroxyvitamin D3 and a high concentration (100 nM) of 1,25-
dihydroxyvitamin D3 also induced HEKa cell differentiation (Fig 4.9C&E). 7-DHC 
(Fig 4.9B) and 10 nM of 1,25-dihydroxyvitamin D3 (Fig 4.9D) did not induce HEKa 
cell differentiation. 
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Figure 4.8 Proliferation of HEKa cells. Untreated cells (A) and cells treated with 
10 µM of vitamin D3 (B), 10 µM 7DHC (C), 10 µM 25(OH)D3 (D), 10 nM 
1,25(OH)2D3 (E), 100 nM 1,25(OH)2D3 (F), 10 µM cholesterol (G), or 10 µM 
cyclopamine (H) for 48 hours. 
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Figure 4.9 Differentiation of HEKa cells after treatment. Measurement of the 
expression of involucrin in HEKa cells after a 48-hour treatment with 10 µM 
vitamin D3 (A), 10 µM 7DHC (B), 10 µM 25(OH)D3 (C), 10 nM 1,25(OH)2D3 (D), 
100 nM 1,25(OH)2D3 (E), 10 µM CaCl2 (F), or 10 µM cyclopamine (G). 
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Effect of cyclopamine on DHCR7 activity 
According to published results (Bijlsma, Spek et al. 2006, Tang, Xiao et al. 2011), 
vitamin D3 may inhibit HEKa cell proliferation by inhibiting the hedgehog signaling 
pathway. In my studies cyclopamine, an inhibitor of hedgehog signaling, inhibited 
HEKa cell proliferation (Fig 4.8H), although not as potently as vitamin D3. Unlike 
vitamin D3, cyclopamine did not induce differentiation of HEKa (Fig 4.9G). This 
led me to investigate the effect of cyclopamine on DHCR7 activity and the 
possibility that hedgehog signaling is involved in the regulation of DHCR7 activity 
by vitamin D3. Interestingly, a 3h pre-treatment with 10 µM of cyclopamine 
decreased DHCR7 activity by 50% (P=0.12), and no further inhibition after 6h 
pre-treatment (Fig 4.10). 
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Figure 4.10 Effect of cyclopamine on DHCR7 activity. Measurement of DHCR7 
activity after 3-h and 6-h pre-treatment with cyclopamine. Values represent the 
mean and S.D. of 3-4 experiments; values that are statistically different from the 
control are indicated by asterisks, as determined by one-way ANOVA analysis of 
variance with Dunnett’s multiple comparisons post hoc test, p < 0.05. 
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Chapter 5: Summary of results 
DHCR7 occupies the pivot-point between cholesterol and vitamin D3 synthesis in 
skin. It is regulated by the SREBP pathway to generate the proper amount of 
cholesterol, but little is known about the regulation of DHCR7 by the vitamin D 
pathway. This is important because DHCR7 activity in skin cells likely affects the 
amount of 7-DHC available for vitamin D3 photosynthesis. It was suggested that 
the photoproduction of vitamin D3 is not only governed by UV light, but more 
importantly, by the availability of 7-DHC, which is entirely derived from 
biosynthesis in the skin (Esvelt, DeLuca et al. 1980). I hypothesized that as 
vitamin D accumulated it might promote the activation of DHCR7 to limit further 
vitamin D production by increasing the conversion of 7-DHC to cholesterol and 
depleting 7-DHC levels in the keratinocyte cell.  An alternative hypothesis was 
that vitamin D might enhance its own production by suppressing DHCR7 activity, 
thereby making more 7-DHC available for photoconversion to vitamin D. 
The first aim of my work was to determine if DHCR7 is regulated by vitamin D3. In 
order to pursue this goal, adult human epidermal keratinocytes (HEKa cells, 
obtained from a commercial supplier) were chosen, as they are primary cells 
harvested from human skin, and are the major cell type responsible for vitamin D 
production. Cultured cells were treated with vitamin D3 at various concentrations 
and for various lengths of time and DHCR7 activity was measured in two ways: in 
cell lysates and in intact cells.  
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Indeed, DHCR7 activity did respond to vitamin D3 treatment. Treatment with 
vitamin D3 resulted in a rapid decrease in DHCR7 activity in as little as 2 hours. 
This rapid down-regulation of DHCR7 activity by vitamin D3 was not due to 
changes in the amount of DHCR7 protein in the cells over the course of the 
experiment. Long-term treatment of HEKa cells with vitamin D3 suppressed 
DHCR7 activity to an even greater degree, and activity did not return fully to pre-
treatment levels even 48 h after removal of vitamin D from the media. I also 
exposed HEKa cells to UVB irradiation on the supposition that 7-DHC in 
keratinocytes would be converted into vitamin D3 and thereby decrease DHCR7 
activity. However, DHCR7 activity did not change in response to UVB irradiation. 
A follow-up study was designed to determine if the hydroxylated forms of vitamin 
D3, 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3, are also able to regulate 
DHCR7 activity in HEKa cells. Compared to the rapid and strong inhibitory effect 
of vitamin D3, the effect of 25-hydroxyvitamin D3 was modest, while 1,25-
dihydroxyvitamin D3, the activated form of the vitamin that binds the vitamin D 
receptor, had no effect on DHCR7 activity. Vitamin D3 rapidly disappeared from 
HEKa cells after addition to the media but I did not see evidence that 25-
hydroxyvitamin D3, or the 1,25-dihydroxy form of the vitamin were being formed. 
Thus, other unidentified metabolites may be responsible for the decrease in 
DHCR7 activity.   
Three other cell lines were also used to evaluate the ability of DHCR7 to respond 
to vitamin D3 treatment: rat hepatoma (McA-RH7777), human hepatoma (HepG2), 
and immortalized human keratinocyte (HaCaT) cells. The rationale was that skin 
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is the only organ exposed to sunlight and where both cholesterol and vitamin D3 
are synthesized. The results were consistent with this rationale in that DHCR7 
from both rat and human hepatoma cells did not respond to vitamin D3 treatment. 
Unexpectedly, vitamin D3 did not affect DHCR7 activity in HaCaT cells. I did note 
that the DHCR7 protein level in HEKa cells was 7-fold lower than that in HepG2 
cells while the activity in HEKa cells was 2-fold greater. 
After treatment of HEKa cells with vitamin D3 for 3 hours, DHCR7 activity 
decreased to 19% of the original levels, but 7-DHC content was unchanged. 
There was also no change in the activity of lathosterol 5-desaturase which 
catalyzes the conversion of lathosterol to 7DHC, the step that immediately 
precedes DHCR7. The content of lanosterol, an intermediate formed further 
upstream in the cholesterol synthesis pathway, was not changed significantly 
after short-term (3 hour) or long-term (24h) treatment with vitamin D3, although 
there was a trend toward a decrease in the content of this vitamin D and 
cholesterol precursor. These results suggest that vitamin D3 rapidly down-
regulates cholesterolgenesis presumably at a very early step in the pathway, as 
neither lanosterol nor 7DHC accumulate in vitamin D3-treated cells. 
Shefer et al. (Shefer, Salen et al. 1998) demonstrated that DHCR7 in rat liver can 
be activated by phosphorylation and inactivated by dephosphorylation. This is the 
only rapid regulation of DHCR7 reported to date. I was able to replicate the 
activation of DHCR7 by ATP in mouse microsomes and in rat hepatoma cells, 
but not in human hepatoma cells nor in human keratinocytes, HaCaT and HEKa. 
 70 
 
In addition, phosphatases such as alkaline phosphatase and protein 
phosphatase 1 did not decrease DHCR7 activity in either keratinocyte line.  
The vitamin D receptor might be expected to be involved in the regulation of 
DHCR7, given that 1,25-dihydroxyvitamin D3 modulates the transcription of 
numerous genes in skin and other tissues. However, DHCR7 activity was not 
affected by 1,25-dihydroxyvitamin D3 treatment, even at a pharmacologic 
concentrations, in either keratinocyte cell line. Therefore, it does not appear that 
the VDR is involved in the rapid regulation of DHCR7 by vitamin D3.   
Other means of suppressing DHCR7 activity, including direct inhibition by vitamin 
D or allosteric modulation of activity were also considered, as AY-9944 and BM 
15.766 are established non-competitive inhibitors of DHCR7, binding either to the 
free enzyme or to the enzyme-substrate complex (Shefer, Salen et al. 1998). I 
did not find evidence for a direct inhibition of DHCR7 by vitamin D3 in my studies. 
Addition of vitamin D3 to HEKa cell lysates did not change DHCR7 activity and 
only extended incubation of the cell lysate with a high concentration of vitamin D3 
produced a decrease in DHCR7 activity. 
An unexpected observation was that vitamin D3 inhibited proliferation and 
induced differentiation of HEKa cells. In healthy adult human skin, keratinocytes 
undergo a continuous process of self-renewal as they progressively differentiate 
and move to the outermost layer of the tissue (Swanson 2004). Little is known 
about the effect of vitamin D3 on this physiologic process even though it has 
been suggested that vitamin D3 inhibits proliferation of basal cell carcinoma 
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through the hedgehog pathway (Tang, Xiao et al. 2011). My studies show that 
vitamin D3, 25-hydroxyvitamin D3, and 1,25-dihydroxyvitamin D3 (100 nM) inhibit 
the growth of HEKa cells. Vitamin D3 also induced differentiation, increasing 
involucrin expression after 48 hours of treatment. 25-Hydroxyvitamin D3 also 
induced involucrin expression, but not as potently as vitamin D3. 1,25-
Dihydroxyvitamin D3 only induced involucrin expression at a high concentration 
(100 nM). 7-DHC and 1,25-dihydroxyvitamin D3 (10 nM) had no effect on HEKa 
cell growth or induction of involucrin expression.  
It has been suggested that vitamin D3 is a potent inhibitor of hedgehog signaling 
(Hh), binding to Smo at the same site as cyclopamine, an inhibitor of Hh and a 
potential agent for cancer therapy (Bijlsma, Spek et al. 2006). Therefore, the 
possible involvement of Hh in vitamin D3-mediated regulation of DHCR7 activity 
was determined by testing the effect of cyclopamine on DHCR7 activity. Although 
not as potent as vitamin D3, treatment of HEKa cells with cyclopamine for 3 hours 
inhibited DHCR7 activity by 50%. This interesting result suggests a possible role 
of Hh in the regulation of DHCR7 by vitamin D3. 
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Chapter 6: Discussion 
Skin is the only organ where both cholesterol and vitamin D3 are synthesized. In 
this dissertation I have attempted to test the hypothesis that the activity of 
DHCR7 governs the availability of 7-DHC for vitamin D3 photoproduction by 
controlling the conversion of 7-DHC to cholesterol. It has been reported that 7-
DHC is entirely derived from biosynthesis in the skin (Esvelt, DeLuca et al. 1980). 
Therefore it is important to understand the regulation of DHCR7 by both end-
products in keratinocytes, the major cell type responsible for vitamin D3 
production in skin. It is well established that DHCR7 is regulated by the SREBP 
pathway to generate proper amounts of cholesterol, but little is known about the 
regulation of DHCR7 by the vitamin D pathway. 
In the present study, I investigated the regulation of DHCR7 by vitamin D3 in 
keratinocytes. By treating cultured HEKa cells with vitamin D3 at various 
concentrations and for various length of time, I determined that vitamin D3 is 
capable of DHCR7 repression. The inhibitory effect is rapid at a pharmacological 
concentration (10 µM), decreasing DHCR7 activity by 70% after treatment for as 
little as 2 hours without changing DHCR7 protein levels. This result suggests that 
vitamin D3 inhibits the conversion of 7-DHC to cholesterol and regulates the 
synthesis of itself in a positive feedback manner. Similar observations were 
published by other groups that chronic dosing of vitamin D-deficient rats with 
1,25-dihydroxyvitamin D3 caused a 4-fold increase of 7-DHC content in skin 
(Esvelt, DeLuca et al. 1980) and long-term (4 weeks) exposure of rats to 
ultraviolet irradiation, which should result in vitamin D3 generation, increased 7-
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DHC content by 60% in skin (Takada 1983). However, unlike these two in vivo 
studies, in my studies 7-DHC content in cultured HEKa cells was not changed 
after a 3-h treatment with vitamin D3. This may be due to high basal levels of 7-
DHC in keratinocytes and/or the short length of treatment. It was shown that the 
7-DHC content of skin was much greater than that found in liver (250:1, µg/g) 
(Takada, Ito et al. 1981). Therefore, although vitamin D3 markedly inhibited 
DHCR7 activity, 7-DHC content was not likely to increase to a significant degree 
in 3 hours. In addition, my studies showed that the lanosterol content and the 
activity of the 7-DHC generating enzyme, lathosterol-5-desaturase, were also 
unchanged, indicating that vitamin D3 rapidly down-regulates cholesterologenesis, 
presumably at a very early step in the pathway. 
In my studies, the regulation of DHCR7 activity by vitamin D3 was found only in 
HEKa cells, and was not evident in rat hepatoma cells, human hepatoma cells, or 
in immortalized human keratinocyte cells. I also observed that DHCR7 protein 
levels in HEKa cells were 7-fold lower than the levels measured in HepG2 cells, 
but the activity was 2-fold higher. Clearly, DHCR7 in keratinocytes exhibits some 
unique characteristics with regard to cholesterologenesis and vitamin D3 
production.  
In 1983, Nemanic et al. suggested that keratinocytes can adjust DHCR7 activity 
over a wide range to control both cholesterologenesis and vitamin D3 generation 
in skin (Nemanic, Whitney et al. 1983). Very few studies had focused on the 
regulation of DHCR7 until 1998 when Shefer et al. suggested that DHCR7 exists 
in two forms: an active phosphorylated form and an inactive dephosphorylated 
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form (Shefer, Salen et al. 1998). In my studies, therefore, I explored possible 
mechanisms by which DHCR7 is regulated, focusing on the rapid inhibitory effect 
of vitamin D3.  
First of all, I tested the possibility that vitamin D3 promotes the dephosphorylation 
of DHCR7. I replicated the activation of DHCR7 by ATP in mouse microsomes 
and rat hepatoma cells, but ATP had no effect on DHCR7 activity in HepG2 cells, 
HaCaT cells, or in HEKa cells, suggesting that the different responses of DHCR7 
to ATP are species- and cell-type dependent. Addition of phosphatases such as 
alkaline phosphatase and protein phosphatase 1 did not decrease DHCR7 
activity in HepG2 or HEKa cells, indicating that dephosphorylation of DHCR7 was 
not likely to be the mechanism by which vitamin D3 inactivates this enzyme in 
HEKa cells. 
Direct inhibition or allosteric modulation of enzyme activity by vitamin D3 was also 
considered as a possible mechanism by which vitamin D3 inactivates DHCR7. 
Incubation of cell lysates with vitamin D3 did not change DHCR7 activity except 
upon incubation in the presence of a very high concentration (100 µM) at 37°C 
for 3 h. This concentration is 10-fold higher than that used to treat cells. This lack 
of a direct effect of vitamin D3 on DHCR7 raised the possibility that vitamin D3 
binds to a membrane receptor on whole cells, initiating a signaling cascade to 
decrease DHCR7 activity. It was reported recently that vitamin D3 can bind with 
high affinity to the membrane protein “smoothened” (Smo), to inhibit hedgehog 
signaling (Bijlsma, Spek et al. 2006). Hedgehog (Hh) plays a role in development 
and stimulates carcinogenesis when dysregulated (Tang, Xiao et al. 2011). 
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Interestingly, vitamin D3 inhibited proliferation and induced differentiation of 
HEKa cells after a 48 h treatment. In support of the report that vitamin D3 serves 
as an inhibitor of Hh signaling by binding to Smo, cyclopamine, a known inhibitor 
of hedgehog signaling, also decreased DHCR7 activity in HEKa cells after a 3 h 
treatment. Testing the possible involvement of hedgehog signaling in the 
regulation of DHCR7 by vitamin D3 certainly warrants further investigation; one 
interesting experiment would be to determine the effect of vitamin D3 on DHCR7 
activity in Smo -/- animal models. 
Esvelt et al. suggested that the vitamin D receptor was involved in the increase of 
7-DHC content in rat skin induced by 1,25-dihydroxyvitamin D3 (Esvelt, DeLuca 
et al. 1980). This is possible because in their study rats were given 1,25-
dihydroxyvitamin D3 subcutaneously for 7 days, long enough for increases in the 
transcription and translation of vitamin D receptor target genes, resulting in the 
accumulation of 7-DHC. On the other hand, it has also been suggested that 1,25-
dihydroxyvitamin D3 is able to exert a direct and rapid action on its target cells by 
binding to membrane receptors other than the traditional vitamin D receptor 
(Nemere, Schwartz et al. 1998). In my study, however, DHCR7 in HEKa cells did 
not respond to low nor high concentrations of 1,25-dihydroxyvitamin D3 after a 3 
h treatment. 
In my study, vitamin D3 rapidly disappeared from HEKa cells after addition to the 
media but I did not see evidence that 25-hydroxyvitamin D3, nor the 1,25-
dihydroxy form of the vitamin were being formed. Thus, other unidentified 
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metabolites may be ultimately responsible for the more prolonged decrease in 
DHCR7 activity. 
Takada suggested that the accumulation of 7-DHC after ultraviolet irradiation 
might be due to the ability of photosynthesized vitamin D3 to prevent the 
conversion of 7-DHC to cholesterol (Takada 1983). In my study I showed that 
vitamin D3 treatment decreased DHCR7 activity in HEKa cells. However, DHCR7 
activity in HEKa cells was not affected by UVB irradiation. This discrepancy may 
be due to different systems (in vivo vs. in vitro). Although HEKa cells are primary 
cells harvested from human skin, keratinocytes in cultured media may be 
different from those in epidermis in terms of 7-DHC content, DHCR7 protein level, 
and enzymatic activities. The response of DHCR7 to UVB irradiation may also 
require an epidermal microenvironment which is absent in monolayer culture. In 
addition, the exposure of HEKa cells to UVB irradiation in vitro might not 
generate enough vitamin D3 to decrease DHCR7 activity. Nemanic et al. 
(Nemanic, Whitney et al. 1983) were first able to show the production of vitamin 
D3 in monolayer human keratinocytes by exposing the cells to UVB with total 
dose of 5000 J/m2. These cells were also pre-treated with AY-9944, an inhibitor 
of DHCR7, resulting in the accumulation of a large quantity of 7-DHC to ensure 
the production of vitamin D3. In my study the cells received a much lower dose of 
UVB (100 J/m2 or 200 J/m2) and no DHCR7 inhibitor was present. This 50-fold 
lower level of UVB exposure is commonly used in vitro for DNA repair and 
immunosuppression studies (Enk, Sredni et al. 1995) but may have been 
insufficient to generate enough vitamin D3 to regulate DHCR7. In order to 
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determine the response of DHCR7 to UVB irradiation, a better in vitro system 
needs to be developed. 
In summary, vitamin D3 inhibited DHCR7 activity at a pharmacological 
concentration only in HEKa cells. Whether vitamin D3 regulates DHCR7 activity 
at lower, and perhaps more physiological concentrations is unclear. However, the 
decrease in DHCR7 activity, the overall decrease in cholesterologenesis, and the 
inhibition of proliferation and promotion of differentiation may all be mediated 
through the inhibition of hedgehog signaling by vitamin D3. 
 
 
 
 
 
 
 
 
 
 
Copyright © Ling Zou 2013 
 78 
 
References 
Ahn, J., K. Yu, R. Stolzenberg-Solomon, K. C. Simon, M. L. McCullough, L. 
Gallicchio, E. J. Jacobs, A. Ascherio, K. Helzlsouer, K. B. Jacobs, Q. Li, S. J. 
Weinstein, M. Purdue, J. Virtamo, R. Horst, W. Wheeler, S. Chanock, D. J. 
Hunter, R. B. Hayes, P. Kraft and D. Albanes (2010). "Genome-wide association 
study of circulating vitamin D levels." Hum Mol Genet 19(13): 2739-2745. 
Alonso, L. and E. Fuchs (2003). "Stem cells of the skin epithelium." Proc Natl 
Acad Sci U S A 100 Suppl 1: 11830-11835. 
Andersson, S., D. L. Davis, H. Dahlback, H. Jornvall and D. W. Russell (1989). 
"Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 
26-hydroxylase, a bile acid biosynthetic enzyme." J Biol Chem 264(14): 8222-
8229. 
Angel, A. and J. Farkas (1974). "Regulation of cholesterol storage in adipose 
tissue." J Lipid Res 15(5): 491-499. 
Bale, A. E. and K. P. Yu (2001). "The hedgehog pathway and basal cell 
carcinomas." Hum Mol Genet 10(7): 757-762. 
Bhatnagar, D., H. Soran and P. N. Durrington (2008). "Hypercholesterolaemia 
and its management." BMJ 337: a993. 
Bijlsma, M. F., M. P. Peppelenbosch and C. A. Spek (2006). "A dual role for 7-
dehydrocholesterol reductase in regulating Hedgehog signalling?" Development 
133(20): 3951; author reply 3952-3953. 
Bijlsma, M. F., C. A. Spek, D. Zivkovic, S. van de Water, F. Rezaee and M. P. 
Peppelenbosch (2006). "Repression of smoothened by patched-dependent (pro-
)vitamin D3 secretion." PLoS Biol 4(8): e232. 
Bikle, D. D. (2011). "Vitamin D metabolism and function in the skin." Mol Cell 
Endocrinol 347(1-2): 80-89. 
Bikle, D. D., H. Elalieh, J. Welsh, D. Oh, J. Cleaver and A. Teichert (2013). 
"Protective role of vitamin D signaling in skin cancer formation." J Steroid 
Biochem Mol Biol 136: 271-279. 
Bikle, D. D., M. K. Nemanic, E. Gee and P. Elias (1986). "1,25-Dihydroxyvitamin 
D3 production by human keratinocytes. Kinetics and regulation." J Clin Invest 
78(2): 557-566. 
Bikle, D. D., D. Ng, C. L. Tu, Y. Oda and Z. Xie (2001). "Calcium- and vitamin D-
regulated keratinocyte differentiation." Mol Cell Endocrinol 177(1-2): 161-171. 
Brown, M. S. and J. L. Goldstein (1997). "The SREBP pathway: regulation of 
cholesterol metabolism by proteolysis of a membrane-bound transcription factor." 
Cell 89(3): 331-340. 
Burger, K., G. Gimpl and F. Fahrenholz (2000). "Regulation of receptor function 
by cholesterol." Cell Mol Life Sci 57(11): 1577-1592. 
Chen, H. W., A. A. Kandutsch and C. Waymouth (1974). "Inhibition of cell growth 
by oxygenated derivatives of cholesterol." Nature 251(5474): 419-421. 
Christakos, S., M. Hewison, D. G. Gardner, C. L. Wagner, I. N. Sergeev, E. 
Rutten, A. G. Pittas, R. Boland, L. Ferrucci and D. D. Bikle (2013). "Vitamin D: 
beyond bone." Ann N Y Acad Sci 1287: 45-58. 
 79 
 
Cooper, M. K., C. A. Wassif, P. A. Krakowiak, J. Taipale, R. Gong, R. I. Kelley, F. 
D. Porter and P. A. Beachy (2003). "A defective response to Hedgehog signaling 
in disorders of cholesterol biosynthesis." Nat Genet 33(4): 508-513. 
Elias, P. M. and K. R. Feingold (1988). "Lipid-related barriers and gradients in the 
epidermis." Ann N Y Acad Sci 548: 4-13. 
Espenshade, P. J. and A. L. Hughes (2007). "Regulation of sterol synthesis in 
eukaryotes." Annu Rev Genet 41: 401-427. 
Esvelt, R. P., H. F. DeLuca, J. K. Wichmann, S. Yoshizawa, J. Zurcher, M. Sar 
and W. E. Stumpf (1980). "1,25-Dihydroxyvitamin D3 stimulated increase of 7,8-
didehydrocholesterol levels in rat skin." Biochemistry 19(26): 6158-6161. 
Feingold, K. R. (2007). "Thematic review series: skin lipids. The role of epidermal 
lipids in cutaneous permeability barrier homeostasis." J Lipid Res 48(12): 2531-
2546. 
Fitzky, B. U., M. Witsch-Baumgartner, M. Erdel, J. N. Lee, Y. K. Paik, H. 
Glossmann, G. Utermann and F. F. Moebius (1998). "Mutations in the Delta7-
sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome." Proc 
Natl Acad Sci U S A 95(14): 8181-8186. 
Gallet, A., L. Ruel, L. Staccini-Lavenant and P. P. Therond (2006). "Cholesterol 
modification is necessary for controlled planar long-range activity of Hedgehog in 
Drosophila epithelia." Development 133(3): 407-418. 
Goldstein, J. L. and M. S. Brown (1977). "The low-density lipoprotein pathway 
and its relation to atherosclerosis." Annu Rev Biochem 46: 897-930. 
Goldstein, J. L. and M. S. Brown (1990). "Regulation of the mevalonate 
pathway." Nature 343(6257): 425-430. 
Grubauer, G., K. R. Feingold and P. M. Elias (1987). "Relationship of epidermal 
lipogenesis to cutaneous barrier function." J Lipid Res 28(6): 746-752. 
Hanukoglu, I. (1992). "Steroidogenic enzymes: structure, function, and role in 
regulation of steroid hormone biosynthesis." J Steroid Biochem Mol Biol 43(8): 
779-804. 
Herman, G. E. (2003). "Disorders of cholesterol biosynthesis: prototypic 
metabolic malformation syndromes." Hum Mol Genet 12 Spec No 1: R75-88. 
Holick, M. F. (2007). "Vitamin D deficiency." N Engl J Med 357(3): 266-281. 
Holick, M. F., J. A. MacLaughlin and S. H. Doppelt (1981). "Regulation of 
cutaneous previtamin D3 photosynthesis in man: skin pigment is not an essential 
regulator." Science 211(4482): 590-593. 
Holick, M. F., N. M. Richtand, S. C. McNeill, S. A. Holick, J. E. Frommer, J. W. 
Henley and J. T. Potts, Jr. (1979). "Isolation and identification of previtamin D3 
from the skin of rats exposed to ultraviolet irradiation." Biochemistry 18(6): 1003-
1008. 
Horton, J. D., J. L. Goldstein and M. S. Brown (2002). "SREBPs: activators of the 
complete program of cholesterol and fatty acid synthesis in the liver." J Clin 
Invest 109(9): 1125-1131. 
Hosomi, J., J. Hosoi, E. Abe, T. Suda and T. Kuroki (1983). "Regulation of 
terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-
dihydroxyvitamin D3." Endocrinology 113(6): 1950-1957. 
 80 
 
Ingham, P. W., Y. Nakano and C. Seger (2011). "Mechanisms and functions of 
Hedgehog signalling across the metazoa." Nat Rev Genet 12(6): 393-406. 
Iwai, I., H. Han, L. den Hollander, S. Svensson, L. G. Ofverstedt, J. Anwar, J. 
Brewer, M. Bloksgaard, A. Laloeuf, D. Nosek, S. Masich, L. A. Bagatolli, U. 
Skoglund and L. Norlen (2012). "The human skin barrier is organized as stacked 
bilayers of fully extended ceramides with cholesterol molecules associated with 
the ceramide sphingoid moiety." J Invest Dermatol 132(9): 2215-2225. 
Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck and D. J. Mangelsdorf (1996). 
"An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha." 
Nature 383(6602): 728-731. 
Jira, P. E., H. R. Waterham, R. J. Wanders, J. A. Smeitink, R. C. Sengers and R. 
A. Wevers (2003). "Smith-Lemli-Opitz syndrome and the DHCR7 gene." Ann 
Hum Genet 67(Pt 3): 269-280. 
Kuwabara, P. E. and M. Labouesse (2002). "The sterol-sensing domain: multiple 
families, a unique role?" Trends Genet 18(4): 193-201. 
Lauth, M., V. Rohnalter, A. Bergstrom, M. Kooshesh, P. Svenningsson and R. 
Toftgard (2010). "Antipsychotic drugs regulate hedgehog signaling by modulation 
of 7-dehydrocholesterol reductase levels." Mol Pharmacol 78(3): 486-496. 
Lee, M. H., D. Gordon, J. Ott, K. Lu, L. Ose, T. Miettinen, H. Gylling, A. F. 
Stalenhoef, A. Pandya, H. Hidaka, B. Brewer, Jr., H. Kojima, N. Sakuma, R. 
Pegoraro, G. Salen and S. B. Patel (2001). "Fine mapping of a gene responsible 
for regulating dietary cholesterol absorption; founder effects underlie cases of 
phytosterolaemia in multiple communities." Eur J Hum Genet 9(5): 375-384. 
Liscum, L. and N. J. Munn (1999). "Intracellular cholesterol transport." Biochim 
Biophys Acta 1438(1): 19-37. 
Lu, K., M. H. Lee and S. B. Patel (2001). "Dietary cholesterol absorption; more 
than just bile." Trends Endocrinol Metab 12(7): 314-320. 
Lu, L., H. Sheng, H. Li, W. Gan, C. Liu, J. Zhu, R. J. Loos and X. Lin (2012). 
"Associations between common variants in GC and DHCR7/NADSYN1 and 
vitamin D concentration in Chinese Hans." Hum Genet 131(3): 505-512. 
Lund, E. G., T. A. Kerr, J. Sakai, W. P. Li and D. W. Russell (1998). "cDNA 
cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane 
proteins that synthesize a potent oxysterol regulator of lipid metabolism." J Biol 
Chem 273(51): 34316-34327. 
MacLaughlin, J. A., R. R. Anderson and M. F. Holick (1982). "Spectral character 
of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in 
human skin." Science 216(4549): 1001-1003. 
Maxfield, F. R. and D. Wustner (2002). "Intracellular cholesterol transport." J Clin 
Invest 110(7): 891-898. 
Moebius, F. F., B. U. Fitzky, J. N. Lee, Y. K. Paik and H. Glossmann (1998). 
"Molecular cloning and expression of the human delta7-sterol reductase." Proc 
Natl Acad Sci U S A 95(4): 1899-1902. 
Monger, D. J., M. L. Williams, K. R. Feingold, B. E. Brown and P. M. Elias (1988). 
"Localization of sites of lipid biosynthesis in mammalian epidermis." J Lipid Res 
29(5): 603-612. 
 81 
 
Nakanishi, M., J. L. Goldstein and M. S. Brown (1988). "Multivalent control of 3-
hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product 
inhibits translation of mRNA and accelerates degradation of enzyme." J Biol 
Chem 263(18): 8929-8937. 
Nemanic, M. K., J. Whitney, S. Arnaud, S. Herbert and P. M. Elias (1983). 
"Vitamin D3 production by cultured human keratinocytes and fibroblasts." 
Biochem Biophys Res Commun 115(2): 444-450. 
Nicoll, P. A. and T. A. Cortese, Jr. (1972). "The physiology of skin." Annu Rev 
Physiol 34: 177-203. 
Omkumar, R. V., B. G. Darnay and V. W. Rodwell (1994). "Modulation of Syrian 
hamster 3-hydroxy-3-methylglutaryl-CoA reductase activity by phosphorylation. 
Role of serine 871." J Biol Chem 269(9): 6810-6814. 
Osborne, T. F., J. L. Goldstein and M. S. Brown (1985). "5' end of HMG CoA 
reductase gene contains sequences responsible for cholesterol-mediated 
inhibition of transcription." Cell 42(1): 203-212. 
Pillai, S., D. D. Bikle and P. M. Elias (1988). "1,25-Dihydroxyvitamin D production 
and receptor binding in human keratinocytes varies with differentiation." J Biol 
Chem 263(11): 5390-5395. 
Porter, J. A., K. E. Young and P. A. Beachy (1996). "Cholesterol modification of 
hedgehog signaling proteins in animal development." Science 274(5285): 255-
259. 
Proksch, E., J. M. Brandner and J. M. Jensen (2008). "The skin: an 
indispensable barrier." Exp Dermatol 17(12): 1063-1072. 
Proksch, E., P. M. Elias and K. R. Feingold (1990). "Regulation of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase activity in murine epidermis. Modulation of 
enzyme content and activation state by barrier requirements." J Clin Invest 85(3): 
874-882. 
Proksch, E., K. R. Feingold and P. M. Elias (1992). "Epidermal HMG CoA 
reductase activity in essential fatty acid deficiency: barrier requirements rather 
than eicosanoid generation regulate cholesterol synthesis." J Invest Dermatol 
99(2): 216-220. 
Quesney-Huneeus, V., H. A. Galick, M. D. Siperstein, S. K. Erickson, T. A. 
Spencer and J. A. Nelson (1983). "The dual role of mevalonate in the cell cycle." 
J Biol Chem 258(1): 378-385. 
Repa, J. J. and D. J. Mangelsdorf (2000). "The role of orphan nuclear receptors 
in the regulation of cholesterol homeostasis." Annu Rev Cell Dev Biol 16: 459-
481. 
Russell, D. W. (1999). "Nuclear orphan receptors control cholesterol catabolism." 
Cell 97(5): 539-542. 
Shefer, S., G. Salen, A. Honda, A. K. Batta, L. B. Nguyen, G. S. Tint, Y. A. 
Ioannou and R. Desnick (1998). "Regulation of rat hepatic 3beta-hydroxysterol 
delta7-reductase: substrate specificity, competitive and non-competitive inhibition, 
and phosphorylation/dephosphorylation." J Lipid Res 39(12): 2471-2476. 
Singh, D. K., S. Banerjee and T. D. Porter (2009). "Green and black tea extracts 
inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol 
synthesis in hepatoma cells." J Nutr Biochem 20(10): 816-822. 
 82 
 
Siperstein, M. D. (1984). "Role of cholesterogenesis and isoprenoid synthesis in 
DNA replication and cell growth." J Lipid Res 25(13): 1462-1468. 
Smith, E. L., N. C. Walworth and M. F. Holick (1986). "Effect of 1 alpha,25-
dihydroxyvitamin D3 on the morphologic and biochemical differentiation of 
cultured human epidermal keratinocytes grown in serum-free conditions." J 
Invest Dermatol 86(6): 709-714. 
Stumpf, W. E., M. Sar, F. A. Reid, Y. Tanaka and H. F. DeLuca (1979). "Target 
cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, 
pituitary, and parathyroid." Science 206(4423): 1188-1190. 
Swanson, H. I. (2004). "Cytochrome P450 expression in human keratinocytes: an 
aryl hydrocarbon receptor perspective." Chem Biol Interact 149(2-3): 69-79. 
Tang, J. Y., T. Z. Xiao, Y. Oda, K. S. Chang, E. Shpall, A. Wu, P. L. So, J. Hebert, 
D. Bikle and E. H. Epstein, Jr. (2011). "Vitamin D3 inhibits hedgehog signaling 
and proliferation in murine Basal cell carcinomas." Cancer Prev Res (Phila) 4(5): 
744-751. 
te Pas, M. F., P. Lombardi, L. M. Havekes, J. Boonstra and M. Ponec (1991). 
"Regulation of low-density lipoprotein receptor expression during keratinocyte 
differentiation." J Invest Dermatol 97(2): 334-339. 
Vance, D. E. and H. Van den Bosch (2000). "Cholesterol in the year 2000." 
Biochim Biophys Acta 1529(1-3): 1-8. 
Vantieghem, K., A. M. Kissmeyer, P. De Haes, R. Bouillon and S. Segaert (2006). 
"UVB-induced production of 1,25-dihydroxyvitamin D3 and vitamin D activity in 
human keratinocytes pretreated with a sterol delta7-reductase inhibitor." J Cell 
Biochem 98(1): 81-92. 
Wang, T. J., F. Zhang, J. B. Richards, B. Kestenbaum, J. B. van Meurs, D. Berry, 
D. P. Kiel, E. A. Streeten, C. Ohlsson, D. L. Koller, L. Peltonen, J. D. Cooper, P. 
F. O'Reilly, D. K. Houston, N. L. Glazer, L. Vandenput, M. Peacock, J. Shi, F. 
Rivadeneira, M. I. McCarthy, P. Anneli, I. H. de Boer, M. Mangino, B. Kato, D. J. 
Smyth, S. L. Booth, P. F. Jacques, G. L. Burke, M. Goodarzi, C. L. Cheung, M. 
Wolf, K. Rice, D. Goltzman, N. Hidiroglou, M. Ladouceur, N. J. Wareham, L. J. 
Hocking, D. Hart, N. K. Arden, C. Cooper, S. Malik, W. D. Fraser, A. L. 
Hartikainen, G. Zhai, H. M. Macdonald, N. G. Forouhi, R. J. Loos, D. M. Reid, A. 
Hakim, E. Dennison, Y. Liu, C. Power, H. E. Stevens, L. Jaana, R. S. Vasan, N. 
Soranzo, J. Bojunga, B. M. Psaty, M. Lorentzon, T. Foroud, T. B. Harris, A. 
Hofman, J. O. Jansson, J. A. Cauley, A. G. Uitterlinden, Q. Gibson, M. R. 
Jarvelin, D. Karasik, D. S. Siscovick, M. J. Econs, S. B. Kritchevsky, J. C. Florez, 
J. A. Todd, J. Dupuis, E. Hypponen and T. D. Spector (2010). "Common genetic 
determinants of vitamin D insufficiency: a genome-wide association study." 
Lancet 376(9736): 180-188. 
Williams, M. L., A. M. Mommaas-Kienhuis, S. L. Rutherford, S. Grayson, B. J. 
Vermeer and P. M. Elias (1987). "Free sterol metabolism and low density 
lipoprotein receptor expression as differentiation markers of cultured human 
keratinocytes." J Cell Physiol 132(3): 428-440. 
Zhou, J. X., L. W. Jia, W. M. Liu, C. L. Miao, S. Liu, Y. J. Cao and E. K. Duan 
(2006). "Role of sonic hedgehog in maintaining a pool of proliferating stem cells 
in the human fetal epidermis." Hum Reprod 21(7): 1698-1704. 
 83 
 
Ziboh, V. A. and R. S. Chapkin (1988). "Metabolism and function of skin lipids." 
Prog Lipid Res 27(2): 81-105. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84 
 
VITA 
Ling Zou, B.S. 
Academic Degrees 
• 2009-Present, Graduate Program in Pharmaceutical science, College of 
Pharmacy, University of Kentucky, Lexington, KY 
• 2008 B.S., Pharmaceutical science, Chengdu University of Traditional 
Chinese Medicine, Chengdu, Sichuan Province, P.R. China. 
Professional Experiences 
• Aug 2009-Present, Research Assistant, College of Pharmacy, University 
of Kentucky. Mentor: Todd Porter, Ph.D. 
Honors and Awards 
• Kentucky Opportunity Fellowship 2012 – 2013 
• Best Abstract Competition 3rd place, Experimental Biology 2012, 
Integrative Systems, Translational and Clinical Pharmacology Division, 
American Society for Pharmacology and Experimental Therapeutics, April, 
2012. 
• ISTCP Young Investigators Award Platform 3rd place, Experimental 
Biology 2012, Integrative Systems, Translational and Clinical 
Pharmacology Division, American Society for Pharmacology and 
Experimental Therapeutics, April, 2012. 
Publications 
• Porter TD, Banerjee S, Stolarczyk EI, Zou L (2011) Suppression of 
cytochrome P450 reductase expression in hepatoma cells replicates the 
hepatic lipidosis observed in hepatic POR-null mice. Drug Metab. Dispos. 
39, 966-973. 
 85 
 
• Zou L., Li L., Porter TD (2011) 7-Dehydrocholesterol reductase activity is 
independent of cytochrome P450 reductase. J. Steroid Biochem. Mol. Biol. 
127, 435-438. 
• Riddick DS, Ding X, Wolf CR, Porter TD, Pandey AV, Zhang QY, Gu J, 
Finn RD, Ronseaux S, McLaughlin LA, Henderson CJ, Zou L, Fluck CE 
(2013) NADPH-Cytochrome P450 Oxidoreductase: Roles in Physiology, 
Pharmacology and Toxicology. Drug Metab. Dispos. 41, 12-23. 
Oral Presentations 
• Regulation of 7-Dehydrocholesterol Reductase by Vitamin D, Drug 
Discovery Division, Department of Pharmaceutical Sciences, May, 2011. 
• Cholecalciferol Increases 7-Dehydrocholesterol Reductase Activity in 
Adult Human Epidermal Keratinocytes, Drug Discovery Division, 
Department of Pharmaceutical Sciences, February, 2012. 
• Cholecalciferol increases 7-dehydrocholesterol reductase activity in adult 
human epidermal keratinocytes, ISTCP Young Investigators Award 
Platform Session, Experimental Biology 2012, Integrative Systems, 
Translational and Clinical Pharmacology Division, American Society for 
Pharmacology and Experimental Therapeutics, April, 2012. 
Conference Abstracts 
• Zou, L., Li, L., and Porter, T.D. (2009) Cytochrome P450 reductase is not 
necessary for 7-dehydrocholesterol reductase activity. Gill Heart Institute 
Cardiovascular Research Day, Oct 15, Lexington, KY. 
• Zou, L., Li, L., and Porter, T.D. (2011) 7-dehydrocholesterol reductase 
does not require cytochrome P450 reductase for activity. Congress on 
Steroid Research, Mar 27-29, Chicago, IL. 
• Zou, L. and Porter, T.D. (2012) Cholecalciferol increases 7-
dehydrocholesterol reductase activity in adult human epidermal 
keratinocytes. Experimental Biology, Apr 21-25, San Diego, CA.  
